Entries |
Document | Title | Date |
20080199934 | Functional peptide fiber, production method thereof and method for recovering peptide chains - This invention provides a functional peptide fiber which comprises a plurality of peptide structure units each containing at least one peptide chain, wherein peptide chains contained in each adjacent peptide structure units do not form peptide bond but are structured into a fibrous form by taking a β-sheet structure, and wherein at least one of the plurality of peptide structure units contains a peptide chain having a functional material connected thereto. Also disclosed are a method for producing the functional peptide fiber and a method for recovering peptide chains from the functional peptide fiber. | 08-21-2008 |
20080299638 | Pharmaceutical Composition and Method of Treating Hepatitis with Arginases - The invention discloses methods for treating hepatitis with human arginase I modified by polyethylene glycol and uses of it in manufacturing of a medicament. | 12-04-2008 |
20080318294 | Biomolecular Hybrid Material and Process for Preparing Same and Uses for Same - Disclosed is a composition and method for fabricating novel hybrid materials comprised of, e.g., carbon nanotubes (CNTs) and crosslinked enzyme clusters (CECs). In one method, enzyme-CNT hybrids are prepared by precipitation of enzymes which are subsequently crosslinked, yielding crosslinked enzyme clusters (CECs) on the surface of the CNTs. The CEC-enzyme-CNT hybrids exhibit high activity per unit area or mass as well as improved enzyme stability and longevity over hybrid materials known in the art. The CECs in the disclosed materials permit multilayer biocatalytic coatings to be applied to surfaces providing hybrid materials suitable for use in, e.g., biocatalytic applications and devices as described herein. | 12-25-2008 |
20090081756 | Nucleic acid-enzyme complex - The present invention provides a method for controlling cleavage of a target RNA by deoxyribozyme. | 03-26-2009 |
20090081757 | Adsorbents Comprising Anthraquinone Dye-Ligends for the Separation of Biological Materials - A process for the separation of biological materials, such as dye-ligand affinity chromatography, wherein an adsorbent is used, which comprises a reaction product of certain reactive anthroquinone compounds and a substrate having a group capable of reaction with a reactive group in said reactive anthroquinone compounds to form a covalent bond. | 03-26-2009 |
20090081758 | Chimeric Cytochrome P450 Proteins and Methods of Use - The present invention provides chimeric cytochrome P450 enzymes fused to heterologous reductase domains to generate single-component, self-sufficient, more cost-effective and catalytically more active biosynthetic P450 monooxygenases. | 03-26-2009 |
20090081759 | NUCLEIC ACID ENCODING A NOVEL RIBONUCLEASE HAVING AN AMINO ACID SEQUENCE MADE UP OF THE AMINO ACID SEQUENCE OF A KNOWN RIBONUCLEASE AND AN N-TERMINAL LEADER SEQUENCE THAT IS AT LEAST ONE RESIDUE LONG - A nucleic acid encodes a novel RNase. The RNase has an amino acid sequence in which an amino acid sequence disclosed in United States Patent U.S. Pat. No. 6,239,257 B1 is preceded by a different N-terminal residue or leader sequence. | 03-26-2009 |
20090104678 | METHOD OF PRODUCING POLYSACCHARIDE DERIVATIVES - A polysaccharide derivative having a high solubility in an aqueous solvent is produced. The production method of the present invention uses a compound shown by the general formula (1) as a condensing agent and allows a polysaccharide having a carboxyl group to react with an an organic compound having a functional group capable of condensing with the carboxyl group to prepare the polysaccharide derivative: | 04-23-2009 |
20090111158 | IMMOBILIZED MICROBIAL NITRILASE FOR PRODUCTION OF GLYCOLIC ACID - The present invention provides a process for preparing an enzyme catalyst having nitrilase activity for hydrolysis of glycolonitrile to glycolic acid with improved retention of recovered catalyst activity in consecutive batch reactions with catalyst recycle, said process comprising pretreating the enzyme catalyst with glutaraldehyde. The glutaraldehyde-pretreated enzyme catalyst has improved specific activity when compared to non-glutaraldehyde-pretreated enzyme catalysts, and thereby, has improved overall catalyst activity and productivity. | 04-30-2009 |
20090197317 | TSG-Like Gene - A gene encoding a novel protein that is homologous to | 08-06-2009 |
20090203104 | TAB Molecules - The present invention relates to TAB molecules, ADEPT constructs directed against TAG-72, and their use in therapy. | 08-13-2009 |
20090263880 | MUTANT LUCIFERASE - An object of the present invention is to provide a mutant luciferase having luciferase activity with an altered emission spectrum. A specific amino acid residue(s) is substituted in a luciferase derived from | 10-22-2009 |
20090269825 | METHOD FOR STABILIZATION OF BIOLOGICAL MOLECULE AND COMPOSITION - The object is to provide a method for stabilization of a biological molecule and a composition, specifically a method for stabilization of an enzyme or a labeled antibody for use in a clinical diagnosis and a composition. Thus, disclosed is a method for stabilization of a biological molecule which is characterized by allowing (a) the biological molecule and (b) sericin and/or a hydrolysate or equivalence thereof to coexist with each other. Also disclosed is a composition having a biological molecule stabilized therein, which is characterized in that the components (a) and (b) coexist with each other in the composition. Further disclosed is a composition for stabilizing a biological molecule, which comprises sericin and/or a hydrolysate or equivalence thereof. | 10-29-2009 |
20090275101 | Pancreatic Cancer Genes - The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia. | 11-05-2009 |
20090280550 | Polymer-Factor IX Moiety Conjugates - Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the conjugates. | 11-12-2009 |
20090298154 | Conjugated biological molecules and their preparation - Novel biologically active compounds of the general formula (I) in which one of X and X′ represents a polymer, and the other represents a hydrogen atom; each Q independently represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; or, if X′ represents a polymer, X-Q-W— together may represent an electron withdrawing group; and in addition, if X represents a polymer, X′ and electron withdrawing group W together with the interjacent atoms may form a ring; each of Z | 12-03-2009 |
20100003736 | Polynucleotides encoding novel PCSK9 variants - The present invention provides novel polynucleotides encoding PCSK9b and PCSK9c polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel PCSK9b and PCSK9c polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention. | 01-07-2010 |
20100015684 | FACTOR VII: REMODELING AND GLYCOCONJUGATION OF FACTOR VII - The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide. | 01-21-2010 |
20100055761 | METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORAL TARGETING - The present invention provides methods and compositions for treating various diseases through selective killipg of targeted cells using a combinatorial targeting approach. The invention features protoxin fusion proteins containing a cell targeting moiety and, a modifiable activation moiety which is activated by an activation moiety not naturally operably found in, on, or in the vicinity of a target cell. These methods also include the combinatorial use of two or more therapeutic agents, at minimum comprising a protoxin and a protoxin activator, to target and destroy a specific cell population. | 03-04-2010 |
20100075392 | METHOD FOR REMOVING ORGANIC SOLVENT - An object of the present invention is to provide a method for efficiently removing a residual organic solvent in a biopolymer structure. The present invention provides a method for removing an organic solvent contained in a biopolymer structure from the structure, (1) wherein the structure is placed in an atmosphere containing a solvent other than the organic solvent so as to remove the organic solvent, or (2) wherein the organic solvent is removed by washing the structure with a solution mainly containing water, or (3) wherein the structure contains a hydrophilic compound. | 03-25-2010 |
20100093056 | ANTIBODIES THAT BIND DKK-RELATED PROTEINS - Novel Dkk and Dkk-related polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Dkk and Dkk-related proteins, the invention further provides isolated fusion proteins, antigenic peptides and antibodies. The invention also provides Dkk and Dkk-related nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Dkk and Dkk-related gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. | 04-15-2010 |
20100129890 | Cytochrome P450 enzyme complexes and methods of treatment using the same - The present invention provides methods and compositions for balancing electron reduction potentials of formulations in a manner that reduces susceptibility to changes from xenobiotics. The present invention also provides novel compositions of matter based on structuring from a mobile nucleotide integral to its architecture. | 05-27-2010 |
20100173381 | CRYSTAL STRUCTURES OF HIV-1 PROTEASE INHIBITORS BOUND TO HIV-1 PROTEASE - Described herein are methods for rational design of inhibitors of HIV-1 protease, and crystal structures of HIV-1 protease inhibitors bound to HIV-1 protease. | 07-08-2010 |
20100173382 | HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGATES - Chimeric and humanized anti-5T4 antibodies and antibody/drug conjugates and methods for preparing and using the same. | 07-08-2010 |
20100173383 | Nuclear Factor Of Activated T Cells Receptor - The present invention provides a novel transmembrane protein, which is a nuclear factor of activated T cells (‘NFAT’) receptor, and related compositions and methods. | 07-08-2010 |
20100173384 | METHODS FOR PROTEIN LABELING BASED ON ACYL CARRIER PROTEIN - A method for labeling acyl carrier protein (ACP) fusion proteins with a wide variety of different labels is disclosed. The method relies on the transfer of a label from a coenzyme A type substrate to an ACP fusion protein using a holo-acyl carrier protein synthase (ACPS) or a homologue thereof. The method allows detecting and manipulating the fusion protein, both in vitro and in vivo, by attaching molecules to the fusion proteins that introduce a new physical or chemical property to the fusion protein. Examples of such labels are, among others, spectroscopic probes or reporter molecules, affinity tags, molecules generating reactive radicals, cross-linkers, ligands mediating protein-protein interactions or molecules suitable for the immobilization of the fusion protein. | 07-08-2010 |
20100184184 | Production of Conjugates - Disclosed is a method for indirectly coupling a small molecule ligand to a molecule to be labelled with the ligand, the method comprising the step of: contacting a scaffold molecule, to which is attached at least one small molecule ligand, with the molecule to be labelled, the scaffold molecule having at least one group which is reactive towards a receiver moiety present or formed in situ on the molecule to be labelled, so as to forma bond between the scaffold molecule and the molecule to be labelled, thereby indirectly coupling the small molecule ligand to the molecule to be labelled. | 07-22-2010 |
20100221807 | CELLULASE ENZYME AND METHOD FOR PRODUCING THE SAME - This invention provides a cellulase enzyme derived from intestinal symbiotic protists of insects selected from the group consisting of | 09-02-2010 |
20100221808 | POLYSIALIC ACID DERIVATIVES - A polysialic acid compound is reacted with a hetero-bifunctional reagent to introduce a pendant functional group for site-specific conjugation to sulfhydryl groups, for instance side chains of cysteine units in drugs, drug delivery systems, proteins or peptides. The functional group is, for instance, an N-maleimide group. | 09-02-2010 |
20100227374 | PROTEIN STABILIZATION BY DOMAIN INSERTION INTO A THERMOPHILIC PROTEIN - A strategy to improve protein stability by domain insertion. TEM 1 beta-lactamase (BLA) and exo-inulinase, as model target enzymes, are inserted into a hyperthermophilic maltose binding protein from | 09-09-2010 |
20100233779 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites - The present invention concerns methods and compositions for delivery of therapeutic agents to target cells, tissues or organisms. In preferred embodiments, the therapeutic agents are delivered in the form of therapeutic-loaded polymers that may comprise many copies of one or more therapeutic agents. In more preferred embodiments, the polymer may be conjugated to a peptide moiety that contains one or more haptens, such as HSG. The agent-polymer-peptide complex may be delivered to target cells by, for example, a pre-targeting technique utilizing bispecific or multispecific antibodies or fragments, having at least one binding arm that recognizes the hapten and at least a second binding arm that binds specifically to a disease or pathogen associated antigen, such as a tumor associated antigen. Methods for synthesizing and using such therapeutic-loaded polymers and their conjugates are provided. | 09-16-2010 |
20100248326 | STABILIZATION OF THERMOLYSIN IN AQUEOUS SOLUTION - The present invention deals with the proteolytic enzyme thermolysin which tends to be unstable in aqueous solution. The invention provides methods and compositions to enhance the stability of dissolved thermolysin in aqueous solution. Thermolysin, crude thermolysin or a lyophilisate containing thermolysin and one or more salts, is contacted with an aqueous buffer with a low salt concentration and a first solution is formed. Subsequently, a further salt in solid form is added and dissociated, thereby forming a second solution comprising thermolysin in a stabilized form. | 09-30-2010 |
20100255558 | SUPRAMOLECULAR BIOCONJUGATES - The invention relates to supramolecular bioconjugates and to methods for assembling and utilizing supramolecular bioconjugates. Supramolecular bioconjugates comprise a plurality of first nucleic acids and a plurality of mediators wherein each mediator comprises a second nucleic acid complementary to a sequence within said plurality of first nucleic acids. To assemble a supramolecular bioconjugate, one or more sets of bioreactive agents are coupled to the plurality of mediators, forming a plurality of bioreactive complexes. The plurality of bioreactive complexes are hybridized to the plurality of first nucleic acids to form the supramolecular bioconjugate. Bioconjugates can be used to detect and isolate targets, to screen samples for targets such as antigens, to treat patients with multiple agents or to diagnose disorders in the form of a kit. | 10-07-2010 |
20100261247 | Active surface coupled polymerases - Active surface coupled polymerases, surfaces that include such polymerases, and methods of making and using surface-attached polymerases are provided. | 10-14-2010 |
20100261248 | Pharmaceutical Composition Comprising An Immunoglobulin FC Region as a Carrier - Disclosed is a novel use of an immunoglobulin Fc fragment, and more particularly, a pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier. The pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier remarkably extends the serum half-life of a drug while maintaining the in vivo activity of the drug at relatively high levels. Also, when the drug is a polypeptide drug, the pharmaceutical composition has less risk of inducing immune responses compared to a fusion protein of the immunoglobulin Fc fragment and a target protein, and is thus useful for developing long-acting formulations of various polypeptide drugs. | 10-14-2010 |
20100273233 | AMYLOID SPECIFIC PEPTIDES AND USES THEREOF - Phage peptide display technology was used to identify peptides that bind specifically to the amyloid form of the Aβ | 10-28-2010 |
20100285564 | Anticalins - The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using generic engineering methods. Alike immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures. | 11-11-2010 |
20100297725 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use - A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically to two or more different targets. The two or more specific binding moieties are conjugated to different haptens, and at least one of the haptens is an oxazole, a pyrazole, a thiazole, a nitroaryl compound other than dinitrophenyl, a benzofurazan, a triterpene, a urea, a thiourea, a rotenoid, a coumarin, a cyclolignan, a heterobiaryl, an azo aryl, or a benzodiazepine. The sample is contacted with two or more different anti-hapten antibodies that can be detected separately. The two or more different anti-hapten antibodies may be conjugated to different detectable labels. | 11-25-2010 |
20100297726 | STABILIZED TRANSGLUTAMINASE AND PROCESS FOR PRODUCTION THEREOF - Disclosed is a transglutaminase having excellent stability. Also disclosed is a process for producing the transglutaminase. Specifically disclosed is a stabilized transglutaminase, which has such a structure in which a pro-sequence peptide of transglutaminase is bound to a mature transglutaminase. Also specifically disclosed is a process for producing stabilized transglutaminase, which includes the steps of: culturing a microorganism capable of producing transglutaminase under the conditions where transglutaminase can be produced; and separating and collecting matured transglutaminase having a pro-sequence peptide bound thereto from a culture medium. | 11-25-2010 |
20100323420 | REGULATED APOPTOSIS - We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells. | 12-23-2010 |
20100323421 | METHOD FOR CHEMICALLY MODIFYING BIOPOLYMER AND POLYPEPTIDE - It is an object of the present invention to provide a method for chemically modifying biopolymer and polypeptide with a hydrophobic compound or a compound which causes degradation or reaction under basic condition. The present invention provides a method for producing a chemically modified biopolymer or polypeptide, wherein a biopolymer or polypeptide is chemically modified in a reaction solution containing an organic fluorine compound. | 12-23-2010 |
20100323422 | PEG-Urate Oxidase Conjugates and Use Thereof - A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme. | 12-23-2010 |
20100330645 | ONE POT DESIALYLATION AND GLYCOPEGYLATION OF THERAPEUTIC PEPTIDES - The present invention provides conjugates between peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention. | 12-30-2010 |
20110014675 | Poly zinc finger proteins with improved linkers - Polynucleotides encoding chimeric proteins, and methods for their production and use are disclosed. The chimeric proteins comprise a flexible linker between two zinc finger DNA-binding domains, wherein the linker contains eight or more amino acids between the second conserved histidine residue of the carboxy-terminal zinc finger of the first domain and the first conserved cysteine residue of the amino-terminal zinc finger of the second domain. | 01-20-2011 |
20110014676 | PROTEIN STABILIZATION - A method and formulation for temperature stabilization of proteins, such as antibodies, enzymes such as Taq poly-merase, restriction enzymes, and other diagnostic or therapeutic enzymes using a combination of first and second stabilizers. | 01-20-2011 |
20110020895 | METHODS AND COMPOSITIONS FOR DETERMINING ISOMERASE ENZYMATIC ACTIVITY - This disclosure provides crystalline flavonoid or flavanone isomerases, isolated non-native isomerase having the structural coordinates of said crystalline isomerase, and nucleic acids encoding such non-native isomerase. Also disclosed are methods of predicting the activity and/or substrate specificity of a putative isomerase, methods of identifying potential ismerase substrates, and methods of identifying potential isomerase inhibitors. | 01-27-2011 |
20110039324 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS - The present invention is directed to compositions of matter useful for the enhancement of apoptosis in mammals and to methods of using those compositions of matter for the same. | 02-17-2011 |
20110053244 | NOVEL PROTEIN DELIVERY SYSTEM TO GENERATE INDUCED PLURIPOTENT STEM (iPS) CELLS OR TISSUE-SPECIFIC CELLS - A novel protein delivery system to generate induced pluripotent stem (iPS) cells is described. The delivery system comprises a construct with a receptor binding domain that recognizes a receptor in a somatic cell, a translocation domain that allows the transfer of an inducer into the cytosolic space, and a cargo bearing domain to which the inducer is attached and facilitates transfer of the inducer into the cell. | 03-03-2011 |
20110059502 | MULTIPLE DOMAIN PROTEINS - Described herein are methods and compositions for generating and using fusion proteins. | 03-10-2011 |
20110081702 | Method for the Production of Proteins - The present invention relates to a process for the purification of a protease. | 04-07-2011 |
20110086404 | METHOD FOR MONITORING, DIAGNOSING, AND SCREENING CANCER THROUGH MEASURING THE CONCENTRATION OF DES-R PROTHROMBIN ACTIVATION PEPTIDE FRAGMENT F2 (DES-R F2) IN A SERUM - The present invention relates to a method for diagnosis and screening of cancer by measuring the expression of des-R prothrombin activation peptide fragment F2 (des-R F2) in serum, more precisely, des-R-prothrombin activation peptide fragment F2 which is the protein marker down-regulated specifically in liver cancer, breast cancer, and stomach cancer, and a method for diagnosis and screening of liver cancer, breast cancer, and stomach cancer by quantifying the protein marker. The protein marker of the present invention can be effectively used for diagnosis and screening of liver cancer, breast cancer and stomach cancer by comparing the expression of the said protein marker in a normal subject with that of a liver cancer, breast cancer, or stomach cancer patients. | 04-14-2011 |
20110091957 | PROTEIN-POLYMER CONJUGATES AND SYNTHESIS THEREOF - A method of synthesizing a protein-polymer conjugate includes the steps: covalently attaching at least one controlled radical polymerization initiator to a protein to form a protein-initiator composition; and mixing the protein-initiator composition with at least one monomer which undergoes controlled radical polymerization in the presence of the protein-initiator composition under conditions suitable to initiate the controlled radical polymerization. | 04-21-2011 |
20110104782 | CRYSTAL STRUCTURE OF AURORA-2 PROTEIN AND BINDING POCKETS THEREOF - The present invention provides crystalline molecules or molecular complexes which comprise binding pockets of Aurora-2 or its homologues. The invention also provides crystals comprising Aurora-2. The present invention also relates to a computer comprising a data storage medium encoded with the structural coordinates of Aurora-2 binding pockets and methods of using a computer to evaluate the ability of a compound to bind to the molecule or molecular complex. This invention also provides methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. In addition, this invention provides methods of using the structure coordinates to screen for and design compounds, including inhibitory compounds, that bind to Aurora-2 or homologues thereof. | 05-05-2011 |
20110104783 | STEREOISOMER PEPTIDES, LIGAND-TARGETED MULTI- STEREOISOMER PEPTIDE POLYMER CONJUGATES, AND USES THEREOF - The invention provides compounds of the formula Poly-([SP-LI]n-PL-L2) including a collection of 152 peptides useful to create the compounds, and their uses thereof for the treatment of a variety of mammalian diseases. The compound, a novel ligand-targeted multi-stereoisomer peptide polymer conjugate, comprises two or more stereoisomer peptides and a peptide-ligand conjugated via linkers to a biocompatible hydrophilic polymer, preferably HPMA. The increased stability and solubility of the compound carrying the stereoisomer peptides and a peptide-ligand provide ideal pharmaceutical properties including the delivery by the polymer of the peptides into the target cells. The compounds of the invention are useful therapeutics for the treatment of a variety of mammalian diseases. Examples of such diseases in human patients include abnormal angiogenesis, pathological conditions of the eye, cancer, metastasis, diabetes, Alzheimer's and Parkinson's diseases, brain and neurodegenerative disorders, bipolar disorder, and diseases caused by aging and pathogen agents, to name a few. | 05-05-2011 |
20110124081 | NUCLEAR FACTOR OF ACTIVATED T CELLS RECEPTOR - The present invention provides a novel transmembrane protein, which is a nuclear factor of activated T cells (“NEAT”) receptor, and related compositions and methods. | 05-26-2011 |
20110129894 | SECRETION OPTIMIZED MICROORGANISM - Proteins having a cofactor can be secreted in an improved manner in a microorganism belonging to the genus | 06-02-2011 |
20110136201 | HETEROCYCLE-SUBSTITUTED XANTHENE DYES - The present invention relates to fluorescent dyes in general. The present invention provides a wide range of fluorescent dyes and kits containing the same, which are applicable for labeling a variety of biomolecules, cells and microorganisms. The present invention also provides various methods of using the fluorescent dyes for research and development, forensic identification, environmental studies, diagnosis, prognosis, and/or treatment of disease conditions. | 06-09-2011 |
20110143416 | STABILIZATION OF DEHYDROGENASES WITH STABLE COENZYMES - The present invention relates to a method for stabilizing an enzyme by storing the enzyme in the presence of a stable coenzyme. The present invention further relates to an enzyme stabilized with a stable coenzyme, and to the use thereof in test elements for detecting analytes. | 06-16-2011 |
20110143417 | Stably Tethered Structures of Defined Compositions with Multiple Functions or Binding Specificities - The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization and docking domain attached to a first precursor, and a second monomer comprising an anchoring domain attached to a second precursor. The first and second precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. The disclosed methods and compositions provide a simple, easy to purify way to obtain any binary compound attached to any monomeric compound, or any trinary compound. | 06-16-2011 |
20110151536 | THROMBIN ACTIVATOR COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Disclosed are compositions for activating thrombin precursors to thrombin. The compositions provided include polypeptide compositions wherein the pre-pro-sequence comprises a thrombin cleavage site. The compositions provided also include polynucleotides encoding said polypeptides and recombinant systems for expressing said polypeptides. This disclosure also relates to methods for producing said compositions, recovering said compositions, activating said compositions purifying said compositions and producing active thrombin molecules using the active form of said compositions. | 06-23-2011 |
20110151537 | Synthetic Catalysts that Separate CO2 from the Atmosphere and Gas Mixtures - The creation of a catalyst that can be used for a wide variety of applications including the steps of developing preliminary information regarding the catalyst, using the preliminary information to produce a template of the catalyst, and using the template of the catalyst to produce the catalyst. | 06-23-2011 |
20110151538 | AFFINITY PURIFICATION BY COHESIN-DOCKERIN INTERACTION - The present invention is directed to truncated dockerin polypeptides, recombinant polypeptides and affinity systems comprising the truncated dockerin polypeptide, methods of generating same, and methods of use thereof to purify, isolate, and detect molecules of interest. | 06-23-2011 |
20110159564 | METHOD FOR STABILIZING COENZYME AND COMPOSITION THEREOF - Disclosed is a sugar and/or a sugar alcohol as a substance for suppressing dephosphorylation reaction of a phosphorylated coenzyme. Also disclosed is a method for stabilizing a phosphorylated coenzyme which is characterized by having at least a substance for suppressing dephosphorylation reaction of the phosphorylated coenzyme coexist with the phosphorylated coenzyme. | 06-30-2011 |
20110159565 | REAGENTS AND PROCESSES FOR STABILIZING ALKALINE PHOSPHATASE OR CONJUGATES THEREOF - The present disclosure relates to stabilizers for alkaline phosphatase or conjugates thereof, a process for preparing a stabilizer, and a method for stabilizing alkaline phosphatase or conjugates thereof with a stabilizer. The present disclosure also relates to a reagent of alkaline phosphatase or conjugates thereof as well as to a process for preparing the same. In another aspect, the present disclosure relates to a kit comprising the stabilizers disclosed herein and alkaline phosphatase or conjugates thereof. The stabilizer disclosed herein can stabilize alkaline phosphatase or conjugates thereof for a prolonged period of time, extending their shelf-life. | 06-30-2011 |
20110159566 | Methods and Reagents for Preparing Multifunctional Probes - Multifunctional probes are synthesized in a single step using peptide scaffold-based multifunctional single-attachment-point reagents. To obtain multifunctional probes using the methods of the invention, a substrate (e.g., a nanoparticle, polymer, antibody, protein, low molecular weight compound, drug, etc.) is reacted with a multifunctional single-attachment-point (MSAP) reagent. The MSAP reagents can include three components: (i) a peptide scaffold, (ii) a single chemically reactive group on the peptide scaffold for reaction of the MSAP with a substrate having a complementary reactive group, and (iii) multiple functional groups on the peptide scaffold. The peptide scaffold can include any number of residues; however, for ease of synthesis and reproducibility in clinical trials, it is preferred to limit the residues in the peptide to 20 or less. The reagent can be prepared to yield a predetermined stoichiometric ratio of the functional groups on the scaffold such that the probe has a fixed stoichiometric ratio of the functional groups. | 06-30-2011 |
20110165647 | NANOPARTICLE CONJUGATES - A nanoparticle conjugate comprising a nanoparticle having one or more peptide-ol compounds and one or more polyethylene glycol (PEG) compounds attached thereto. A method of producing the nanoparticle conjugate is also described. | 07-07-2011 |
20110165648 | Co-crystal structure of factor D and anti-factor D antibody - The present invention is directed towards the co-crystal structure of Factor D and an anti-Factor D antibody or an antigen binding fragment thereof. | 07-07-2011 |
20110165649 | METHODS AND COMPOSITIONS TO IMPROVE THE HEALTH OF PLANTS, ANIMALS AND MICROBES BY MANIPULATING PROTEIN ENTRY INTO SYMBIONTS AND THEIR HOSTS - Fusion constructs with i) a domain that is specific for binding, on the surface of a cell, a lipid that is characteristic of the cell, and ii) a domain or agent that possesses an activity of interest that impacts the cell, are provided. Binding of the fusion construct to the characteristic lipid results in attachment of the construct to the cell and 1) expression of the activity of interest at the cell surface or, 2) entry of the construct into the cell, so that the activity of interest is expressed inside the cell. The cell may be a pathogen, cancer cell or other pathological cell displaying a characteristic lipid, and the domain or agent may be toxic or inhibitory to the cell. Alternatively, the cell may be non-pathogenic and the activity of interest may elicit a desired response from the cell, e.g. cell division, up regulation of a gene sequence, etc. | 07-07-2011 |
20110165650 | Fusion Polypeptides Capable of Activating Receptors - A fusion polypeptide comprising (A) | 07-07-2011 |
20110171714 | CRYSTAL STRUCTURE OF TAK1-TAB1 - The invention relates to molecules or molecular complexes which comprise binding pockets of TAK1 or its structural homologues. The invention relates to crystallizable compositions and crystals comprising TAK1. The present invention also relates to a data storage medium encoded with the structural coordinates of molecules and molecular complexes which comprise the TAK1 or TAK1-like ATP-binding pockets. The present invention also relates to a computer comprising such data storage material. The computer may generate a three-dimensional structure or graphical three-dimensional representation of such molecules or molecular complexes. This invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. In addition, this invention relates to methods of using the structure coordinates to screen for and design compounds, including inhibitory compounds, that bind to TAK1 or homologues thereof. | 07-14-2011 |
20110171715 | BIOCOMPATIBLE POLYMER AND MAGNETIC NANOPARTICLE WITH BIOCOMPATIBILITY - The invention discloses a biocompatible polymer for covalently modifying magnetic nanoparticles. The biocompatible polymer may be coupled to a targeting agent and/or a fluorescent dye. The invention also discloses a magnetic nanoparticle with biocompatibilities comprising the biocompatible polymer. | 07-14-2011 |
20110171716 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF - Provided herein are water-soluble carbohydrate polymers which are monoderivatized at their reducing terminus, such that the carbohydrate polymers can be selectively conjugated at a single location. Also provided are methods of preparation and conjugation of the monoderivatized carbohydrate polymers. | 07-14-2011 |
20110177578 | APTAMER AGAINST IL-17 AND USE THEREOF - The invention provides an aptamer possessing an inhibitory activity against IL-17, as well as a complex comprising an aptamer possessing a binding activity or inhibitory activity against IL-17 and a functional substance (for example, affinity substances, substances for labeling, enzymes, drug delivery vehicles, drugs and the like). The invention also provides a pharmaceutical drug, cell migration inhibitor, diagnostic reagent, detection probe, carrier, labeling agent, and the like comprising the aforementioned aptamer or complex, and methods of detecting and purifying IL-17 by using the aforementioned aptamer or complex. | 07-21-2011 |
20110189751 | METHODS AND COMPOSITIONS COMPRISING HEAT SHOCK PROTEINS - Compositions, and uses thereof, which are beneficial for eukaryotic cells in culture, and methods for their use in promoting cell growth, viability and recombinant protein expression. The methods disclosed in the present application are useful, for example, for improving cell viability and in accelerating the rate of cell growth of cells grown in culture. In one aspect, the supplements of the invention are useful for improving or enhancing the yield of the recombinant proteins from the cell cultures. | 08-04-2011 |
20110189752 | COMPLEX - A complex comprising at least one target protein and at least one binding molecule having a binding affinity for said target protein, wherein said molecule having a binding affinity is covalently or non-covalently bound to at least one water-soluble polymer | 08-04-2011 |
20110189753 | Intracellular Production of a Nuclease - Methods and compositions are provided that relate to obtaining a recombinant DNA and RNA cleaving nuclease. This involves the over-expression of a fusion protein between maltose-binding protein and a truncated nuclease in a soluble form in the cytoplasm of a host cell from which it can be readily extracted. | 08-04-2011 |
20110189754 | FUSION PROTEIN COMPRISING AN E. COLI CHAPERONE PROTEIN AND A HUMAN CHAPERONE PROTEIN - The invention discloses the cloning, expression and uses of a chimeric fusion protein with superior chaperone and folding activities compared to the wild type chaperones. This invention relates to a chimeric fusion protein encoded by a recombinant DNA molecule containing nucleotide sequences coding for a polypeptide binding segment of a non-human chaperone protein and nucleotide sequences coding for an FK506 binding protein (FKBP) or an FK506-binding-protein-like domain (FKBP-like domain). In particular, this invention relates to a chimeric fusion protein encoded by a recombinant DNA molecule containing nucleotide sequences coding for a polypeptide binding segment of a non-human chaperone protein and nucleotide sequences coding for a human FKBP type peptidyl-prolyl-cis/trans isomerase (PPIase), methods of producing these chimeric fusion proteins and their uses as folding helpers in the production of other proteins and in the process of the production of vaccines or pharmaceuticals, and as folding helpers for performing immunoassays. | 08-04-2011 |
20110195478 | BLADDER CANCER BIOMARKER AND TEST METHOD USING THE SAME - The present invention discloses a bladder cancer biomarker and a test method using the same. The biomarker contains at least one of the mentioned 69 compounds, such as apolipoprotein A1 (APOA1), apolipoprotein A2 (APOA2), peroxiredoxin 2 (PRDX2), heparin cofactor 2 precursor (HCII), and serum amyloid A-4 protein (SAA4), which exist in the urine specimen of a testee. The expression intensity of the biomarker can facilitate diagnosis of bladder cancer and evaluation of aggressiveness and malignancy of bladder cancer. Thereby, the physician can arrange an optimized treatment to achieve the best therapeutic effect. | 08-11-2011 |
20110201080 | BIOMOLECULES HAVING MULTIPLE ATTACHMENT MOIETIES FOR BINDING TO A SUBSTRATE SURFACE - Compounds relating to attachment chemistries for binding biomolecules to a substrate surface are described. These include compounds of the following structure: | 08-18-2011 |
20110223645 | Multivalent Carriers of Bi-Specific Antibodies - Provided herein are targetable constructs that are multivalent carriers of bi-specific antibodies, i.e., each molecule of a targetable construct can serve as a carrier of two or more bi-specific antibodies. Also provided are targetable complexes formed by the association of a targetable construct with two or more bi-specific antibodies. The targetable constructs and targetable complexes of the invention are incorporated into biosensors, kits and pharmaceutical compositions, and are used in a variety of therapeutic and other methods. | 09-15-2011 |
20110236951 | Biocomposite materials and methods for making the same - A particle (and a composition that includes a plurality of the particles) that includes at least one polypeptide molecule and at least one polymer covalently bound to the polypeptide molecule so as to form a polymer shell substantially encompassing the polypeptide molecule, wherein the particle does not define a dimension greater than about 1 μm. One example for making the particle includes modifying the polypeptide molecule to provide α, β-ethylenically unsaturated terminal functional groups, mixing the modified polypeptide molecule with a silicon-containing polymerizable compound, and subjecting the resulting mixture to conditions sufficient for polymerizing the polymerizable compound to form the particle. | 09-29-2011 |
20110236952 | NOVEL SUBSTRATES OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE AND MUTANTS THEREOF - The invention relates to compounds of formula (I′): | 09-29-2011 |
20110244544 | Polymeric carriers for immunohistochemistry and in situ hybridization - Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays. | 10-06-2011 |
20110244545 | Polymeric carriers for immunohistochemistry and in situ hybridization - Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays. | 10-06-2011 |
20110244546 | Internalizing Anti-CD74 Antibodies and Methods of Use - The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis. | 10-06-2011 |
20110262991 | Living Copolymer-Protein/Peptide Hybrids for Biomedical Applications - Water soluble polymers having formula I: Y-(L | 10-27-2011 |
20110262992 | METHOD FOR STABILIZING LABELED ANTIBODY - The present invention relates to a method for stabilizing a labeled antibody in a solution, in which the labeled antibody is stabilized by allowing the labeled antibody to be present together with at least one of amino acid and a derivative thereof in the solution. | 10-27-2011 |
20110262993 | METHOD FOR PREPARING A CELLULAR CARBON MONOLITH COMPRISING A HIERARCHISED POROUS NETWORK - A carbon or ceramic monolithic materials with an M2 (macroporous/microporous) hierarchised porous structure is provided as well as method for preparing said materials using a macro/meso/microporous silica cavity. Such materials may be used, in particular for the production of hydrogen purifiers, supercapacitors or electrodes, or else for carrying out catalysed chemical reactions in a heterogeneous phase. | 10-27-2011 |
20110262994 | NOVEL REAGENTS AND METHOD FOR CONJUGATING BIOLOGICAL MOLECULES - A compound of the general formula X-[Q-W—(CH═CH) | 10-27-2011 |
20110269210 | ALPHA-AMYLASE VARIANTS WITH ALTERED PROPERTIES - Disclosed are compositions comprising variants of alpha-amylase that have alpha-amylase activity and that exhibit altered properties relative to a parent AmyS-like alpha-amylase from which they are derived. The compositions generally comprise at least one of an additional enzyme, a detergent,.a surfactant, a chelator, an oxidizing agent, an acidulant, an alkalizing agent, a source of peroxide, a source of hardness, a salt, a detergent complexing agent, a polymer, a stabilizing agent, or a fabric conditioner. Also disclosed are detergent formulations comprising the variants. Methods of using the compositions for desizing woven material and washing or cleaning items, such as dishes or laundry, are disclosed. Kits related thereto are also provided. | 11-03-2011 |
20110275134 | Arrestin Biosensor - The present invention relates to a novel biosensor. A resonance energy transfter (RET) biosensor comprising a beta(β)-arrestin tagged with a first and a second chromophore, wherein said first chromophore is a fluorophore and said second chromophore is a fluorophore or a bioluminophore is described. | 11-10-2011 |
20110281322 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 11-17-2011 |
20110294189 | BIOMOLECULE POLYMER CONJUGATES AND METHODS FOR MAKING THE SAME - Methods for producing biomolecule-polymer conjugates, such as polypeptide-polymer conjugates, include attachment of an initiator agent to a biomolecule and in situ polymerization of a polymer from defined sites on the biomolecule. The conjugates may have desirable pharmacological properties and may be used therapeutically. | 12-01-2011 |
20110300600 | METHODS AND COMPOSITIONS FOR DELIVERING POLYNUCLEOTIDES - Methods and compositions for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal. Methods for modifying the genome of non-nuclear organelles are also provided. | 12-08-2011 |
20110300601 | PROCESSES FOR SYNTHESIZING ALKALINE PHOSPHATASE CONJUGATES - Methods for synthesizing an ALP conjugate are provided. The methods may include activating a carboxyl group of the ALP with a carbodiimide, to generate an active ester; and adding the substance to be conjugated such that a synthetic reaction occurs between the active ester and the substance to be conjugated, to generate an ALP conjugate. | 12-08-2011 |
20110300602 | CONJUGATE PREPARATION METHODS AND RELATED KIT - Methods for preparing conjugates including enzyme conjugates and especially alkaline phosphatase (ALP) conjugates, and a kit are provided. The methods include: blocking an amino group on a molecule surface of a first substance to be conjugated containing an amino group and a carboxyl group (for example, an enzyme) with a carboxyl compound; adding a carbodiimide to activate the first substance to be conjugated with the amino group blocked; inactivating or removing the carbodiimide; and adding a second substance containing an amino group (for example, a substance to be labeled). Conjugates (for example, enzyme conjugates) are obtained. | 12-08-2011 |
20110300603 | Tagged Ligands for Enrichment of Rare Analytes from a Mixed Sample - Method of enriching specific cells from cellular samples are disclosed, comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety, wherein the affinity tags do not comprise a magnetic particle; and flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells. Methods for enriching circulating tumor cells, and devices for enriching specific cells from cellular samples are also disclosed. | 12-08-2011 |
20110318808 | Engineered Plant Cysteine Proteases and Their Uses - The present invention relates to potato virus NIa protease variants or fragments thereof, polynucleotides encoding them, and methods of making and using the foregoing. | 12-29-2011 |
20110318809 | METHOD OF SCREENING PLACENTAL PROTEINS RESPONSIBLE FOR PATHOPHYSIOLOGY OF PREECLAMPSIA, AND MARKER FOR EARLY DIAGNOSIS AND PREDICTION OF PREECLAMPSIA - The present invention relates to a method of screening placental proteins responsible for pathophysiology of preeclampsia, and a marker for early diagnosis and prediction of preeclampsia. In accordance with one aspect of the present invention, there is provided a method of screening placental proteins responsible for pathophysiology of preeclampsia by 2D E-proteomics analysis, comprising: isolating placental proteins from a placental tissue; separating the isolated proteins two-dimensionally through 2D electrophoresis; and comparing and analyzing the separated proteins based on scanned gel images and differences in the images between normal placental proteins and preeclamptic placental proteins, wherein the comparison and analysis of the placental proteins based on the scanned gel images and differences in the images are accomplished by selecting proteins with differences of 140% or more between two placentas. | 12-29-2011 |
20120003713 | Polymerase Enhancing Factor (PEF) Extracts PEF Protein Complexes Isolated PEF Proteins and Methods for Purifying and Identifying - The invention provides novel extracts, proteins, and complexes that improve the polymerization activity of nucleic acid polymerases. Included within the aspects of the invention are methods for identifying compositions with a polymerase enhancing activity, methods for purifying and using these compositions, and specific extracts, proteins, and complexes that function to enhance polymerase activity. As an example, specifically described is nucleotide and amino acid sequence information for a | 01-05-2012 |
20120003714 | BLENDS CONTAINING PROTEASES - Described are compositions, in particular lyophilizates, containing proteolytic enzymes, and methods for producing the compositions. Typically these compositions contain one or more proteases with collagenase activity and a neutral protease, for example, thermolysis. The compositions are free of acetate salts. Surprisingly, such compositions can be dissolved in water more rapidly than lyophilized protease mixtures of the state of the art. | 01-05-2012 |
20120009646 | CHEMICALLY MODIFIED CARBONIC ANHYDRASES USEFUL IN CARBON CAPTURE SYSTEMS - The present disclosure relates to chemically modified carbonic anhydrase polypeptides and soluble compositions, homogenous liquid formulations comprising them. The chemically modified carbonic anhydrase polypeptides have improved properties relative to the same carbonic anhydrase polypeptide that is not chemically modified including the improved properties of increased activity and/or stability in the presence of amine compounds, ammonia, or carbonate ion. The present disclosure also provides methods of preparing the chemically modified polypeptides and methods of using the chemically modified polypeptides for accelerating the absorption of carbon dioxide from a gas stream into a solution as well as for the release of the absorbed carbon dioxide for further treatment and/or sequestering. | 01-12-2012 |
20120021485 | HYBRID ALPHA-AMYLASES - Hybrid alpha-amylases are provided that share a conserved 3D structure in whole or in part with a wild-type Termamyl-like ?-amylase, e.g., a | 01-26-2012 |
20120021486 | ENZYME-BASED NANOSCALE DECONTAMINATING COMPOSITES - The invention relates to decontaminating composites, and methods, compositions, and kits comprising the same. In some aspects, the invention relates to a decontaminating composite, comprising a perhydrolase associated with a carbon nanotube, that is useful for producing peracids. | 01-26-2012 |
20120021487 | METHOD OF TREATING GAUCHER DISEASE - Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof. | 01-26-2012 |
20120028332 | PROCESS FOR PRODUCTION OF AN ENZYME PRODUCT - The invention relates to a process for production of an enzyme product having a plurality of enzyme activities obtained by fermentation of an | 02-02-2012 |
20120034671 | Protein Matrix For Light-Initiated Electron Transfer - The present invention provides selective modification of polypeptide sequences with electron transfer moieties. The resulting polypeptide assemblies represent a novel class of electron transfer complexes that are capable of transferring electrons over very long distances at fast rates. These complexes possess unique structural features which enable the production of bioconductors and photoactive probes. | 02-09-2012 |
20120040430 | Compositions useful for detection or quantification of desirable target molecules, novel dyes, composite dyes, and oligonucleotides or polynucleotides comprising such dyes - The present invention provides dyes, reactive dyes and labeled reagents that may be used in the detection or quantification of desirable target molecules, such as proteins and nucleic acids. Dyes are provided that may be used free in solution where the binding of the dye to the target molecule provides signal generation. Dyes are also provided that comprise reactive groups that may be used to attach the dyes to probes that will bind to desirable target molecules. The novel dyes of the present invention have been modified by the addition of charged and polar groups to provide beneficial properties. | 02-16-2012 |
20120040431 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites - The present invention concerns methods and compositions for delivery of therapeutic agents to target cells, tissues or organisms. In preferred embodiments, the therapeutic agents are delivered in the form of therapeutic-loaded polymers that may comprise many copies of one or more therapeutic agents. In more preferred embodiments, the polymer may be conjugated to a peptide moiety that contains one or more haptens, such as HSG. The agent-polymer-peptide complex may be delivered to target cells by, for example, a pre-targeting technique utilizing bispecific or multispecific antibodies or fragments, having at least one binding arm that recognizes the hapten and at least a second binding arm that binds specifically to a disease or pathogen associated antigen, such as a tumor associated antigen. Methods for synthesizing and using such therapeutic-loaded polymers and their conjugates are provided. | 02-16-2012 |
20120040432 | METHODS AND MATERIALS FOR DELIVERING MOLECULES - This document relates to methods and materials involved in delivering molecules to a mammal. For example, methods and materials for using nanoparticles to increase the half-life and the bioavailability of molecules administered to a mammal are provided. | 02-16-2012 |
20120058536 | POLYMER MADE OF A PRIMARY AMINE FUNCTIONALIZED POLYMER AND A HEMICELLULOSE - The present invention relates to a polymer made of a primary amine functionalized polymer and a hemicellulose e.g. chitosan and xyloglucan, wherein the primary amine functionalized polymer is covalently bound to the hemicellulose, and to a cross-linking agent composition comprising the polymer. A method wherein manufacturing a cellulose containing product comprises the steps of; providing a cellulose containing product; treating said cellulose product with a cellulose adsorbing agent comprising a polymer made of a primary amine functionalized polymer and a hemicellulose e.g. chitosan and xyloglucan, and optionally other additives is also provided. | 03-08-2012 |
20120064599 | HYBRIDIZATION LINKERS - The invention provides method of covalently coupling two or more moieties, the method comprising: (a) providing a first moiety having covalently attached thereto (i) at least one first linker comprising a first hybridizable region and (ii) at least one first group capable of forming a covalent bond; (b) providing a second moiety having covalently attached thereto (i) at least one second linker comprising a second hybridizable region capable of hybridizing to the first hybridizable region and (ii) at least a second group capable of forming a covalent bond with the first group; (c) contacting the first and second moieties under conditions that allow the first and second hybridizable regions to hybridize and link the moieties; and (d) exposing the linked moieties to conditions that allow the formation of a covalent bond between the first and second groups. | 03-15-2012 |
20120064600 | ANTI-5T4 ANTIBODIES AND USES THEREOF - Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same. | 03-15-2012 |
20120070874 | Method for recycling enzyme - In saccharification of cellulose, chimeric β-glucosidase having a region exhibiting thermophilic bacteria-derived β-glucosidase activity and a module combinable to cellulose is used along with cellulosome, and at the completion of saccharification of cellulose, a cellulosic substrate is added to make the chimeric β-glucosidase and cellulosome attach to the cellulosic substrate for separation. | 03-22-2012 |
20120070875 | Amino Acid Sequences which Enhance Peptide Conjugate Solubility - The present invention provides peptide conjugates having improved solubility as well as increased secretion during cell based production, as well as methods of utilizing such peptides. The peptide conjugates include a short peptide domain defined by the amino acid sequence AGIH (SEQ ID NO: 8) and may include a biologically active molecule useful in intracellular and intranuclear transport of the biologically active molecule to treat various disorders and diseases. | 03-22-2012 |
20120083025 | Hybrid Enzymes - The present invention relates to hybrid polypeptides having a first amino acid sequence having endo-amylase activity and a second amino acid sequence having carbohydrate binding activity. The present invention also relates to the use of the hybrid polypeptides in starch processing and baking. | 04-05-2012 |
20120094356 | IN VIVO HALF LIFE INCREASED FUSION PROTEIN OR PEPTIDE MAINTAINED BY SUSTAINED IN VIVO RELEASE, AND METHOD FOR INCREASNG IN VIVO HALF-LIFE USING SAME - The present invention relates to a fusion protein or peptide, the in vivo half-life of which is increased by maintaining in vivo sustained release, and to a method for increasing in vivo half-life using same. A fusion protein or peptide according to the present invention has excellent in vivo stability by binding a physiologically active protein or physiologically active peptide to an alpha-1 antitrypsin or alpha-1 antitrypsin mutant with one or more amino acids mutated to maintain the in vivo sustained release and to significantly increase the half-life thereof in blood (T1/2) compared to an inherent physiologically active protein or physiologically active peptide. Thus, a fusion protein or peptide according to the present invention can be useful in developing a sustained-release preparation of a protein or peptide drug. | 04-19-2012 |
20120094357 | TAB MOLECULES - The present invention relates to TAB molecules, ADEPT constructs directed against TAG-72, and their use in therapy. | 04-19-2012 |
20120100593 | Crystals of membrane proteins - A polypeptide in crystalline form comprises a G-protein coupled receptor (GPCR) with an IC3 loop substituted by an amino acid residue sequence of lysozyme. | 04-26-2012 |
20120107902 | Processes For Forming Amide Bonds And Compositions Related Thereto - The disclosure relates to methods for producing amide bonds and reagents related thereto. In some embodiments, the disclosure relates to methods of producing an amide comprising mixing an O-silylated thionoester and an amine under conditions such that an amide is formed. In another embodiment, the disclosure relates to mixing a thiolacid, a silylating agent, and an amine under conditions such that an amide is formed. | 05-03-2012 |
20120107903 | Mutant Glucose Dehydrogenase - A mutant glucose dehydrogenase having an amino acid sequence at least 80% identical to SEQ ID NO:3 and having glucose dehydrogenase activity, wherein amino acid residues corresponding to positions 326, 365 and 472 of said amino acid sequence are replaced with glutamine, tyrosine and tyrosine, respectively, and wherein said mutant glucose dehydrogenase shows an improved substrate specificity to glucose and a reduced reactivity to disaccharides. | 05-03-2012 |
20120122179 | MEANS FOR PURIFYING A PROTEIN OF BLOOD PLASMA AND METHODS FOR IMPLEMENTING SAME - An affinity substrate for the selective binding of a protein of blood plasma includes a solid substrate material on which are immobilized deoxyribonucleic aptamers specifically binding with the plasma protein. | 05-17-2012 |
20120122180 | INCORPORATION OF TYPE III POLYKETIDE SYNTHASES INTO MULTIDOMAIN PROTEINS OF THE TYPE I AND III POLYKETIDE SYNTHASE AND FATTY ACID SYNTHASE FAMILIES - Recombinant fusion proteins in which intermediates are covalently bound to the fusion proteins and transferred between domains of the fusion proteins are provided. The fusion proteins include proteins having type I polyketide or fatty acid synthase domains fused with type III polyketide synthase domains. Methods of making such recombinant fusion proteins and methods using such proteins to produce polyketide and other products are described. | 05-17-2012 |
20120122181 | METHOD FOR DETERMINING ANTAGONIST ACTIVITY TO A CYTOKININ RECEPTOR - The present invention provides a method for analyzing agonist-activity to a cytokinin receptor, which comprises (1) bringing an examinee substance into contact with a transformed cell into which DNA coding the cytokinin receptor is introduced and (2) measuring the existence or the quantity of intracellular signal transduction from the cytokinin receptor expressed in the transformed cell, and, a method for analyzing antagonist-activity to a cytokinin receptor, which comprises (1) bringing an examinee substance and a substance having agonist-activity to the cytokinin receptor into contact with a transformed cell into which DNA coding the cytokinin receptor is introduced. | 05-17-2012 |
20120129237 | POLYNUCLEOTIDES ENCODING NOVEL PCSK9 VARIANTS - The present invention provides novel polynucleotides encoding PCSK9b and PCSK9c polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel PCSK9b and PCSK9c polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention. | 05-24-2012 |
20120135495 | NEUROTOXINS WITH ENHANCED TARGET SPECIFICITY - Modified neurotoxins that contain protease cleavage sites susceptible uniquely to proteases present in certain tissues are described. The toxins can be selectively activated by proteases in muscle or selectively inactivated by proteases in blood. | 05-31-2012 |
20120135496 | Protein Belonging to the TNF Superfamily Involved in Signal Transduction, Nucleic Acids Encoding Same and Methods of Use Thereof - A method of modulating immune response in an animal is disclosed. Such a method interacting the immature dendritic cells from the animal with an antigen ex vivo so that the immature dendritic cells present the antigen on their surfaces, inducing maturation of the immature dendritic cells ex vivo, and contacting the mature dendritic cells ex vivo with a modulator comprising TRANCE, conservative variants thereof, fragments thereof, analogs or derivatives thereof, or a fusion protein comprising the amino acid sequence of TRANCE, conservative variants thereof, or fragments thereof. After contacting the modulator ex vivo, the mature dendritic cells are introduced into the animal. As a result, immune response in the animal towards the antigen is modulated relative to the immune response against the antigen in an animal in which dendritic cells did not interact with the antigen ex vivo, and did not contact a modulator ex vivo. Preferably, the method of the present invention results in increasing immune response towards the antigen in the animal. | 05-31-2012 |
20120142070 | REHYDRATABLE MATRICES FOR DRY STORAGE OF TAQ POLYMERASE IN A MICROFLUIDIC DEVICE - Formulations for dry storage of PCR reagents are described. These formulations find use in manufacture of self-contained microfluidic card devices for PCR clinical testing in which the reagents are reconstituted at the point of testing. In these cards, TAQ polymerase is stored “on-board” in vitrified dry form without lyophilization or freezing, and is reconstituted by either the sample or a sample eluate during the assay. | 06-07-2012 |
20120149082 | Method For The Preparation Of Cross-Linked Enzyme Aggregates With Improved Properties - The invention relates to a method for the preparation of hybrid cross-linked enzyme-silica aggregates including the steps of taking up enzyme molecules in a solvent, precipitating the enzyme molecules using a precipitation agent, and adding an alkoxysilane and crosslinking the mixture of alkoxysilane and precipitated enzyme aggregates, using a crosslinking agent comprising an aldehyde, to obtain hybrid crosslinked enzyme-silica aggregates. | 06-14-2012 |
20120149083 | PEG-Urate Oxidase Conjugates and Use Thereof - A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme. | 06-14-2012 |
20120149084 | FUSION PROTEINS - The invention provides a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a target cell; a Targeting Moiety that is capable of binding to a Binding Site on the target cell, which Binding Site is capable of undergoing endocytosis to be incorporated into an endocome within the target cell; a protease cleaving site at which site the fusion protein is cleavable by the protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and the translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the target cell. | 06-14-2012 |
20120149085 | FUSION PROTEINS CONTAINING RECOMBINANT CYTOTOXIC RNASES - Recombinant immunotoxins containing a cytotoxic RNAse fused to an antibody or antibody fragment may be produced in mammalian cell culture. Surprisingly, immunotoxins containing a cytotoxic RNAse fused to the N-terminus of one antibody variable domain can be prepared and retain the ability to specifically bind antigen. The immunotoxins may be used in a variety of therapeutic methods for treating diseases or syndromes associated with unwanted or inappropriate cell proliferation or activation. | 06-14-2012 |
20120156750 | COMPOSITIONS AND METHODS FOR DEHYDRATED STORAGE OF ON-BOARD REAGENTS IN MICROFLUIDIC DEVICES - Manufacturing methods and compositions are described for production of self-contained microfluidic cartridge devices with on-board reagents for molecular biological testing. Sensitive reagents are stored in dry form without lyophilization or freezing, and reconstituted at the point of use with either a biological sample or a sample eluate at the point of use. Manufacturing methods include sheet and roll fabrication processes where the reagents are printed in place and sealed within individual microfluidic cartridges before gel vitrification. | 06-21-2012 |
20120164708 | STABILIZED ENZYME COMPOSITIONS - The present invention relates to a composition comprising an enzyme and octanol. Additionally, the present invention relates to a composition comprising a transition metal ion. | 06-28-2012 |
20120171747 | SIGNAL AMPLIFICATION MICROSPHERES, THEIR USE IN ONE-STEP AND MULTI-STEP ANALYTICAL AMPLIFICATION PROCEDURES AND METHODS FOR THEIR PRODUCTION - The present invention relates to microspheres comprising protein signal precursor molecules, or a carrier protein bonded to signal precursor molecules, wherein said signal precursor molecules are activatable to generate a detectable signal whilst remaining bonded to the carrier protein. Also disclosed is a method of making such microspheres comprising the steps of mixing protein molecules with a matrix former in solution; adding a reducing reagent to the mixture; removing the reducing reagent; and removing the matrix former to leave microspheres of protein molecules. Also disclosed are bioassay methods using the microspheres to provide signal amplification, including an amplification cycling procedure. | 07-05-2012 |
20120178138 | MODIFICATIONS OF PEPTIDE COMPOSITIONS TO INCREASE STABILITY AND DELIVERY EFFICIENCY - The disclosed invention relates to methods of modifying peptide compositions to increase stability and delivery efficiency. Specifically, the disclosed invention relates to methods to increase the stability and delivery efficiency of protein kinase C (PKC) modulatory peptide compositions. A “therapeutic peptide composition” comprises a “carrier peptide” and a “cargo peptide.” A “carrier peptide” is a peptide or amino acid sequence within a peptide that facilitates the cellular uptake of the therapeutic peptide composition. The “cargo peptide” is a PKC modulatory peptide. Peptide modifications to either the carrier peptide, the cargo peptide, or both, which are described herein increase the stability and delivery efficiency of therapeutic peptide compositions by reducing disulfide bond exchange, physical stability, reducing proteolytic degradation, and increasing efficiency of cellular uptake. | 07-12-2012 |
20120178139 | ERYTHROCYTE-BINDING THERAPEUTICS - Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. | 07-12-2012 |
20120178140 | Modified Clostridial Toxins with Enhanced Targeting Capabilities For Endogenous Clostridial Toxin Receptor Systems - The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins. | 07-12-2012 |
20120184013 | Inhibitors of BMX non-receptor tyrosine kinase - Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase. | 07-19-2012 |
20120184014 | Photoactive Metal Nitrosyls for Blood Pressure Regulation and Cancer Therapy - Disclosed are nitric oxide delivery agents and methods of their use, more specifically to photoactive compounds, which are able to perform targeted delivery of nitric oxide in vitro and in vivo and are useful for medicinal applications including, but not limited, to blood pressure regulation and cancer treatment. | 07-19-2012 |
20120190096 | MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN - The invention relates to materials and methods of conjugating a water soluble fatty acid derivative to a therapeutic protein comprising contacting the therapeutic protein with an activated water soluble fatty acid derivative under conditions that allow conjugation. | 07-26-2012 |
20120190097 | ANIONIC-CORE COMPOSITION FOR DELIVERY OF THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME - The present invention is directed to compositions comprising a polymer backbone with protective chain and anionic groups, and a cationic therapeutic agent. The present invention is directed to compositions for treating infections, inflammatory diseases, excess growth, and damaged cells and organs. | 07-26-2012 |
20120190098 | FLUOROGENIC COMPOUNDS CONVERTED TO FLUOROPHORES BY PHOTOCHEMICAL OR CHEMICAL MEANS AND THEIR USE IN BIOLOGICAL SYSTEMS - Fluorophores derived from photoactivatable azide-pi-acceptor fluorogens or from a thermal reaction of an azide-pi-acceptor fluorogen with an alkene or alkyne are disclosed. Fluorophores derived from a thermal reaction of an alkyne-pi-acceptor fluorogen with an azide are also disclosed. The fluorophores can readily be activated by light and can be used to label a biomolecule and imaged on a single-molecule level in living cells. | 07-26-2012 |
20120196346 | Methods for Generating Stably Linked Complexes Composed of Homodimers, Homotetramers or Dimers of Dimers and Uses - The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. Other embodiments concern tetramers comprising a first and second homodimer, which may be identical or different. The disclosed methods and compositions provide a facile and general way to obtain homodimers, homotetramers and heterotetramers of virtually any functionality and/or binding specificity. | 08-02-2012 |
20120202262 | PROCESS FOR PRODUCTION OF AN ENZYME PRODUCT - The invention relates to a process for production of an enzyme product having a plurality of enzyme activities obtained by fermentation of an | 08-09-2012 |
20120202263 | Bioactive Macromers and Hydrogels and Methods for Producing Same - The invention concerns macromers, having a molecular weight of at least 2 kDa, comprising at least one unit of the formula P-(protein-P) | 08-09-2012 |
20120202264 | INHIBITORS OF IL2-INDUCIBLE T-CELL KINASE - Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase. | 08-09-2012 |
20120208258 | CONJUGATE OF CATECHOL-MODIFIED POLYETHYLENE GLYCOL WITH PROTEIN OR PEPTIDE AND PREPARATION METHOD THEROF - The present invention relates to a conjugate of a protein or peptide with a polyethylene glycol derivative having catechol, wherein the protein or peptide is mono-PEGylated at the N-terminal with the polyethylene glycol derivative, and to a preparation method thereof. According to the invention, the catechol-PEG derivative can be site-specifically conjugated with the N-terminal amine group of a protein or peptide, so that a homogeneous polyethylene glycol-protein or -peptide conjugate can be obtained in high yield. Unlike a prior art conjugate, the conjugate obtained according to the invention allows the decrease in the activity of the protein to be minimized without chemically modifying the protein, and thus the conjugate has an excellent pharmacological effect. Also, because the conjugate is homogeneous, the process for preparing the conjugate can be simplified. Moreover, the conjugate has uniform biological efficacy in vivo and shows strong resistance to hydrolysis and thus a long in vivo duration time. Accordingly, the conjugate has the effect of increasing the in vivo efficacy and stability of the protein drug. | 08-16-2012 |
20120214220 | XYLANASE COMPOSITION AND METHOD FOR MANUFACTURING THE SAME - A xylanase composition and a method for manufacturing the xylanase composition are provided, wherein the xylanase composition comprises a xylanase and a stabilizer, and the xylanase is from an anaerobic fungus, the stabilizer comprises a polyol, and the content of the polyol is at least 40 wt %, based on the total weight of the xylanase composition. | 08-23-2012 |
20120231519 | Molecular Surface Design of Tyrosine-Derived Polycarbonates for Attachment of Biomolecules - Methods for constructing tyrosine-derived biotinylated polymers. Biotinylated polymers and polymer scaffolds constructed with the biotinylated polymers are also disclosed. | 09-13-2012 |
20120231520 | NOVEL FUSION PROTEINS AND METHOD OF EXPRESSION THEREOF - The present invention relates to novel Prolipase-Bovine trypsinogen (PLBTR) fusion proteins, the genes encoding them, and the production and uses thereof. More specifically, the present invention relates to methods of producing in optimal quantities PLBTR fusion proteins which comprise a heterologous polypeptide which is normally susceptible to autocatalytic activity. More particularly, the present invention relates to fusion proteins which comprise an heterologous polypeptide, such as a serine protease, fused to a lipase signal sequence, which can be expressed by recombinant host cells in desired amounts. The present invention further relates to polynucleotides encoding such fusion proteins, to expression vectors for expression of such fusion proteins, to host cells transformed with such polynucleotides/vectors, and to methods of generating such fusion proteins. | 09-13-2012 |
20120231521 | Transducible Polypeptides For Modifying Metabolism - Methods and compositions for modifying the metabolism of a subject are provided. One embodiment provides a recombinant polypeptide having a polynucleotide-binding domain, a protein transduction domain, and a targeting domain. In a preferred embodiment, the polynucleotide-binding domain includes one or more HMG box domains. | 09-13-2012 |
20120244595 | ARTIFICIAL PEPTIDOGLYCAN LYSING ENZYMES AND PEPTIDOGLYCAN BINDING PROTEINS - The present invention relates to recombinant polypeptides having the activity of binding and lysing of bacteria, comprising at least one enzymatically active domain and at least two bacterial cell binding domains. The present invention further relates to recombinant polypeptide having the activity of binding bacteria, comprising at least two bacterial cell binding domain. Further the present inventions relates to nucleic acid molecules comprising a nucleotide sequence encoding the recombinant polypeptides, vectors and host cells. | 09-27-2012 |
20120244596 | ANTICALINS - The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using generic engineering methods. Alike immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures. | 09-27-2012 |
20120244597 | POLYMER FACTOR VIII MOIETY CONJUGATES - Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient. | 09-27-2012 |
20120244598 | Stabilization of Thermolysin in Aqueous Solution - The present invention deals with the proteolytic enzyme thermolysin which tends to be unstable in aqueous solution. The invention provides methods and compositions to enhance the stability of dissolved thermolysin in aqueous solution. Thermolysin, crude thermolysin or a lyophilisate containing thermolysin and one or more salts, is contacted with an aqueous buffer with a low salt concentration and a first solution is formed. Subsequently, a further salt in solid form is added and dissociated, thereby forming a second solution comprising thermolysin in a stabilized form. | 09-27-2012 |
20120252092 | CLOSTRIDIUM HISTOLYTICUM RECOMBINANT COLLAGENASES AND METHOD FOR THE MANUFACTURE THEREOF - The present invention relates to the production of recombinant collagenases, and in particular describes a method for the production of recombinant | 10-04-2012 |
20120258514 | Kits for analysis of biological samples - Chemically reactive carbocyanine dyes that are intramolecularly crosslinked between the 1-position and 3′-position, their bioconjugates and their uses are described. 1,3′-crosslinked carbocyanines are superior to those of conjugates of spectrally similar 1,1′-crosslinked or non-crosslinked dyes. The invention includes derivative compounds having one or more benzo nitrogens. | 10-11-2012 |
20120258515 | Cytolytic RTX-Toxin From Gallibacterium Anatis - The present invention relates to the field of animal health and in particular the causative agent of a new bacterial poultry disease caused by | 10-11-2012 |
20120270296 | ISOTOPE-DOPED NANO-STRUCTURE AND ISOTOPE LABELED STRUCTURE USING THE SMAE - An isotope-doped nano-structure is provided. The isotope-doped nano-structure includes at least one isotope-doped nano-structure segment having at least two isotopes of the element. The at least two isotopes of the element are mixed uniformly in a certain proportion. The isotope-doped nano-structure can be used for isotope labeling one type of the unlabeled structures such as DNAs, proteins, glucoses, gluconic acids, starches, biotin enzymes, sorbitols, or organic amines. An isotope labeled structure is also provided. | 10-25-2012 |
20120276608 | Multivalent Immunoglobulin-Based Bioactive Assemblies - The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Preferred embodiments concern hexameric stably tethered structures comprising one or more IgG antibody fragments and which may be monospecific or bispecific. The disclosed methods and compositions provide a facile and general way to obtain stably tethered structures of virtually any functionality and/or binding specificity. The stably tethered structures may be administered to subjects for diagnostic and/or therapeutic use, for example for treatment of cancer or autoimmune disease. The stably tethered structures may bind to and/or be conjugated to a variety of known effectors, such as drugs, enzymes, radionuclides, therapeutic agents and/or diagnostic agents. | 11-01-2012 |
20120276609 | Stabilization Of Perhydrolases - Disclosed herein are enzyme powders comprising a spray-dried formulation of at least one CE-7 esterase, at least one oligosaccharide excipient, and optionally at least one surfactant. Also disclosed herein is a process for producing peroxycarboxylic acids from carboxylic acid esters using the aforementioned enzyme powders. Further, disinfectant and laundry care formulations comprising the peracids produced by the processes described herein are provided. | 11-01-2012 |
20120282669 | Solubilized Phospholipids for Stabilizing Nucleic Acid Polymerases - Compositions and methods are provided that relate to solubilized phospholipids and their use in stabilizing nucleic acid polymerases. For example, a phospholipid with a tail containing at least 8 carbons can be solubilized in the presence of an amphipathic molecule. | 11-08-2012 |
20120282670 | COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION OF A BIOLOGICAL PRODUCT - Provided herein are methods, nucleic acids, polypeptides, compositions, and kits relating to the conjugation of a heterologous polypeptide to a molecule of interest during production of the polypeptide in cell culture. In various embodiments, the heterologous polypeptide is linked to a sortase ligation sequence and the molecule of interest is linked to a complementary sortase ligation sequence, such that expression of the heterologous protein in the presence of the molecule of interest and cells expressing a surface-associated sortase with the sortase catalytic domain exposed to the extracellular medium results in ligation of the heterologous polypeptide to the molecule of interest to form a conjugated polypeptide. | 11-08-2012 |
20120282671 | MULTI-ARM POLYETHYLENE GLYCOL DERIVATIVES, CONJUGATES AND GELS OF PHARMACEUTICALS AND THE SAME - A multi-arm polyethylene glycol (I) having different kinds of reactive groups and the uses thereof are disclosed, which is formed by polymerizing ethylene oxide with oligo-pentaerythritol as an initiator, wherein, PEG is same or different and is —(CH2CH2O)m-, the average value of m is an integer of 2-250; I is an integer of 1 or more. The method for producing the multi-arm polyethylene glycol having different kinds of reactive groups, the multi-arm polyethylene glycol active derivatives comprising linking groups X attached to PEG and terminal reactive groups F attached to X, the gels formed by the multi-arm polyethylene glycol active derivatives, the drug conjugates formed by the multi-arm polyethylene glycol active derivatives and drug molecules, and the uses thereof in preparing drugs are also disclosed. | 11-08-2012 |
20120288913 | NOVEL FUSION PARTNERS FOR THE PURPOSE OF CRYSTALLIZING G-PROTEIN COUPLED RECEPTORS - GPCR-fusion partner proteins comprising G protein coupled receptors (GPCRs) of GPCRs and fusion partners such as rubredoxin, cytochrome b562 RIL (Bril, bRIL, BRIL), T4 lysozyme C-terminal fragment (Cterm-T4L), flavodoxin, or xylanase either substituted for some or all of the third intracellular loop of the GPCR between the fifth and sixth helix of the GPCR are described or attached to an terminus or C terminus of the GPCR. GPCR-fusion partner proteins in crystalline form, optionally of a quality suitable for x-ray crystallographic structure determination of the GPCR, are described. Methods of using fusion partners in GPCR-fusion partner proteins to support crystallization of GPCR-fusion partner proteins for x-ray crystallographic structure determination of the GPCR, are described. Methods of identifying other suitable fusion partners through screening of protein data banks are also described. | 11-15-2012 |
20120329126 | HYBRID POLYMERASES HAVING THE ABILITY TO PRODUCE LONG AMPLICONS - The present invention provides DNA polymerases having increased efficiency of amplification of long amplicons. The present invention also provides for methods of amplifying target nucleic acid molecules with the DNA polymerases for increasing the efficiency of amplification of long amplicons. | 12-27-2012 |
20120329127 | THERAPEUTIC PROTEINS WITH INCREASED HALF-LIFE AND METHODS OF PREPARING SAME - The present disclosure relates to materials and methods of conjugating a water soluble polymer to a therapeutic protein. | 12-27-2012 |
20120329128 | FORMULATIONS OF RECOMBINANT FURIN - The present application provides stabilized formulations of furin (e.g., rfurin) containing a sugar, sugar alcohol, and/or non-ionic surfactant. As compared to non-stabilized compositions, the furin formulations disclosed herein retain greater amounts of furin activity and monomeric furin content, while reducing furin aggregation when stored and/or subjected to mechanical stress. Also provided are methods for stably diluting furin (e.g., rfurin) compositions. | 12-27-2012 |
20120329129 | MAGNETIC NANOPARTICLE WITH BIOCOMPATIBILITY - A magnetic nanoparticle is provided in the disclosure. The magnetic nanoparticle includes a magnetic nanoparticle; a biocompatible polymer of the following formula (II) covalently coupled to the magnetic nanoparticle, wherein R | 12-27-2012 |
20120329130 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase. | 12-27-2012 |
20130011900 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE - The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst. | 01-10-2013 |
20130011901 | CYCLIC COMPOUND, METHOD FOR PRODUCING CYCLIC COMPOUND, AND METHOD FOR MODIFYING BIOLOGICAL MOLECULE - The invention aims in establishing a method for modifying biomolecules using a reaction that efficiently modifies biomolecules and is widely applicable. The invention thus provides a cyclic compound containing two triazole rings formed by adding and ligating an azide compound possessing an azido group to each of the two carbon-carbon triple bond sites of an eight-membered cyclic skeleton of a cyclic diyne compound by a double click reaction; a method for producing a cyclic compound using a double click reaction; and a method for modifying biomolecules. | 01-10-2013 |
20130023027 | FUSION PROTEINS OF BACTERIAL LUCIFERASE AS MULTICOLOR LUMINESCENT SENSORS - The present invention discloses systems and methods for altering the color of bacterial bioluminescence via a fusion protein complex by fusing | 01-24-2013 |
20130029399 | METAL SALEN COMPLEX DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF - A metal-salen complex derivative with an excellent yield and stability is provided and a method for producing such a metal-salen complex derivative is provided. The present invention provides: metal-salen complex derivative obtained by allowing a target component composed of at least one of an enzyme, an antibody, an antigen, a peptide, an amino acid, an oligonucleotide, a protein, a nucleic acid, and a medical molecule to bind to a metal-salen complex via an amide bond or a disulfide bond; a method for producing such a metal-salen complex derivative. | 01-31-2013 |
20130040360 | Crystal Structure of the Pro Form of a Matrix Metalloproteinase and an Allosteric Processing Inhibitor - The present invention includes a crystal comprising a complex of the pro form of a matrix metalloprotease (proMMP) and a small-molecule allosteric processing inhibitor that inhibits that activation of the proMMP, methods for identifying small-molecule allosteric processing inhibitors that inhibit the activation of a proMMP, and methods of treatment using small-molecule allosteric processing inhibitors that inhibit the activation of a proMMP. The present invention relates to the crystal structure of a complex of proMMP9 bound to a small-molecule allosteric processing inhibitor that inhibits activation of proMMP9. The invention further relates to the use of the methods and the crystal and related structural information for designing, selecting and/or optimizing small-molecule allosteric processing inhibitors that inhibit activation of proMMP9 and proMMP9 homologues. The present invention also relates to the use of small-molecule allosteric processing inhibitors for the treatment of diseases mediated by inappropriate matrix metalloproteinase (MMP) activity. | 02-14-2013 |
20130040361 | NOVEL ANTIGEN ASSOCIATED WITH THE NEOVASCULATURE OF TUMOUR METASTASES - The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the treatment of tumour metastases. | 02-14-2013 |
20130040362 | Method for Activation and Conjugation of Biomolecules - The present invention is directed to a method for producing a biomolecule conjugate where the method is integrated into a single unit operation. | 02-14-2013 |
20130040363 | LABELED ENZYME COMPOSITIONS, METHODS AND SYSTEMS - Disclosed herein are conjugates comprising a biomolecule linked to a label that have biological activity and are useful in a wide variety of biological applications. For example, provided herein are labeled polymerase conjugates including a polymerase linked to one or more labels, wherein the conjugate has polymerase activity. Such conjugates can exhibit enhanced biological activity and/or superior detectability as compared to conventional labeled polymerases. Also disclosed herein are improved methods for preparing such conjugates, and methods and systems for using such conjugates in biological applications such as nucleotide incorporation, primer extension and single molecule sequencing. | 02-14-2013 |
20130045522 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES - The present invention provides random copolymers containing zwitterions and one or more functional agents, and methods of preparing such random copolymers. | 02-21-2013 |
20130052713 | GH61 GLYCOSIDE HYDROLASE PROTEIN VARIANTS AND COFACTORS THAT ENHANCE GH61 ACTIVITY - The present invention provides various GH61 protein variants comprising various amino acid substitutions. The GH61 protein variants have an improved ability to synergize with cellulase enzymes, thereby increasing the yield of fermentable sugars obtained by saccharification of biomass. In some embodiments, sugars obtained from saccharification are fermented to produce numerous end-products, including but not limited to alcohol. | 02-28-2013 |
20130059359 | Protein Nanorings - The invention provides protein nanorings. | 03-07-2013 |
20130059360 | POLYMER-BASED COMPOSITIONS AND CONJUGATES OF ANTIMICROBIAL AGENTS - Provided herein are water-soluble polymer conjugates and polymer-based compositions of antimicrobial agents. Also provided are methods for synthesizing and administering such conjugates and compositions. | 03-07-2013 |
20130084618 | PHENOLIC BINDING PEPTIDES - The present application relates to peptides which bind to tannin, polyphenolic or anthocyanin compounds, and particularly to tea and wine stains on a fabric or other surface. The invention also concerns binding peptide conjugates which includes a binding peptide coupled to an agent and the use of the binding peptide conjugate for delivering an agent to a desired target. | 04-04-2013 |
20130084619 | MODIFIED CELLULASES WITH ENHANCED THERMOSTABILITY - The present invention relates to modified family-8 cellulases that exhibit enhanced thermostability compared to the corresponding wild-type enzyme, polynucleotides encoding the modified cellulases, compositions comprising same and uses thereof. The variant family-8 cellulases are advantageous for the bioconversion process of cellulosic substrates. | 04-04-2013 |
20130095547 | METHOD FOR SELECTIVE CONJUGATION OF ANALYTES TO ENZYMES WITHOUT UNWANTED ENZYME-ENZYME CROSS-LINKING - A method of preparing an analyte-enzyme conjugate where the enzyme contains free, surface-accessible carboxyl moieties without generating undesired, cross-linked enzymes, while preserving the functionality of the enzyme. The method involves treating an enzyme with a blocking agent such that the free carboxyl moieties become non-reactive prior to the conjugation reaction with the desired analyte. The invention is further directed to analyte-enzyme conjugates prepared by the inventive method and to kits which contain an analyte-enzyme conjugate prepared by the methods herein for the detection and/or quantitation of an analyte in a sample. | 04-18-2013 |
20130095548 | ACTIVATED SIALIC ACID DERIVATIVES FOR PROTEIN DERIVATISATION AND CONJUGATION - Derivatives of PSAs are synthesised, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems. | 04-18-2013 |
20130095549 | TWEAK RECEPTOR - The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue. | 04-18-2013 |
20130102049 | REMOVABLE SACCHARIDE-BENZIMIDAZOLE (BIM) TAGS AND CONJUGATES THEREOF VIA 1H-POSITION OF THE BENZIMIDAZOLES - Novel method and reagents for generating reversibly tagged saccharides, aldehydes, carboxyl acids, or orthoacetates useful in analytical and diagnostic applications are disclosed. Saccharides are coupled at the reducing end to tagging moieties comprising a reagent selected from a ortho-diaminobenzoic(DAB)-peptide, an aldo-imidazole or N-methylated aldo-imidazole, or an ortho-phenyldiamine (OPD) or substituted OPD. The tagged saccharide further comprising detectable or functional groups coupled to the tagging moiety are provided. Kits and reagents for chromatography and mass spectrometry are disclosed. | 04-25-2013 |
20130109073 | Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology | 05-02-2013 |
20130109074 | POLYMER-ENCAPSULATED CARBON CAPTURE LIQUIDS THAT TOLERATE PRECIPITATION OF SOLIDS FOR INCREASED CAPACITY | 05-02-2013 |
20130115674 | Human Monoclonal Antibodies to Human Nucleolin - The present invention provides for methods of producing human monoclonal antibodies to human nucleolin, cells producing such antibodies, and the antibodies themselves. Also provided are methods of using the antibodies in diagnosing and treating malignant and non-malignant diseases wherein cells that express nucleolin on the cell surface contribute to the pathophysi-ology of the disease. | 05-09-2013 |
20130130347 | CONSTRUCTS AND METHODS FOR THE ASSEMBLY OF BIOLOGICAL PATHWAYS - The present invention is directed to a synthetic nucleic acid scaffold comprising one or more subunits, each subunit comprising two or more different protein-binding sequences coupled together. The present invention further relates to systems and methods for assembling a synthetic biological pathway and producing a biological pathway product or a precursor product using the synthetic nucleic acid scaffold. | 05-23-2013 |
20130130348 | Polymers for Functional Particles - A method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. The nanoparticle may contain a drug. The moiety may include a polypeptide or a polynucleotide, such as an aptamer. The moiety may be a targeting moiety, an imaging moiety, a chelating moiety, a charged moiety, or a therapeutic moiety. Another aspect is directed to systems and methods of producing such polymeric conjugates. In some embodiments, a solution containing a polymer is contacted with a liquid, such as an immiscible liquid, to form nanoparticles containing the polymeric conjugate. Other methods use such libraries, use or administer such polymeric conjugates, or promote the use of such polymeric conjugates. Kits involving such polymeric conjugates are also described. | 05-23-2013 |
20130130349 | COOPERATIVE AND DYNAMIC ASSEMBLY OF AFFINITY COMPLEXES - The invention generally relates to the field of immunochemistry including antibody therapy, diagnostics, and basic research and specifically relates to the area of alternatives to natural antibodies including artificial antibodies or antibody mimics. The invention relates particularly to the cooperative assembly of stable affinity complexes. | 05-23-2013 |
20130130350 | OBLIGATE HETERODIMER VARIANTS OF FOKI CLEAVAGE DOMAIN - Disclosed are methods of making and using engineered FokI cleavage domain variants. Also disclosed are methods, compositions and fusion proteins containing obligate heterodimers of engineered FokI cleavage domain variants and DNA binding domains, such as zinc finger protein (ZFP) domains and transcription activator-like effector (TALE) domains. | 05-23-2013 |
20130137157 | GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA - The present invention provides conjugates between Factor VII or Factor VIIa peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention. | 05-30-2013 |
20130137158 | LIGAND FUNCTIONALIZED POLYMERS - Ligand functionalized substrates, methods of making ligand functionalized substrates, and methods of using functionalized substrates are disclosed. | 05-30-2013 |
20130137159 | LIPASE-CONTAINING POLYMERIC COATINGS FOR THE FACILITATED REMOVAL OF FINGERPRINTS - A substrate or coating is provided that includes a lipase with enzymatic activity toward a component of a fingerprint. Also provided is a process for facilitating the removal of fingerprints is provided wherein an inventive substrate or coating including a lipase is capable of enzymatically degrading of one or more components of the fingerprint to facilitate fingerprint removal from the substrate or said coating. Applying heat to the substrate or coating increases the rate of fingerprint removal. | 05-30-2013 |
20130143294 | NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS - The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof. | 06-06-2013 |
20130143295 | AMYLASES AND GLUCOAMYLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM - In one aspect, the invention is directed to polypeptides having an amylase and/or glucoamylase activity, polynucleotides encoding the polypeptides, and methods for making and using these polynucleotides and polypeptides. In one aspect, the polypeptides of the invention can be used as amylases, for example, alpha amylases, to catalyze the hydrolysis of polysaccharide, oligosaccharide or starch into sugars. In one aspect, the invention provides delayed release compositions comprising an desired ingredient coated by a latex polymer coating. In alternative embodiments, enzymes are used to make biofuels, e.g., ethanol, butanol, propanol, or a gasoline-ethanol mix, including a bioethanol, biopropanol, biobutanol, or a biodiesel, or for any form of fuel or biomass processing. | 06-06-2013 |
20130143296 | Delivery System for Cytotoxic Drugs by Bispecific Antibody Pretargeting - The present invention relates to methods and compositions for pretargeting delivery of therapeutic agents. In preferred embodiments, the pretargeting method comprises: a) administering a bispecific antibody with a first binding site for a disease-associated antigen and a hapten on a targetable construct; b) administering a targetable construct comprising at least one therapeutic agent. In preferred embodiments, the bispecific antibody is made by the dock-and-lock (DNL) technique. In a more preferred embodiment, the targetable construct comprises one or more SN-38 moieties. | 06-06-2013 |
20130143297 | STABILIZED LIQUID TENSIDE PREPARATION COMPRISING ENZYMES - A hydrolytic enzyme is to be stabilized in a liquid surfactant preparation. This is achieved by using a component that stabilizes the hydrolytic enzyme and encompasses an aminophthalic acid. | 06-06-2013 |
20130143298 | STABILIZED LIQUID TENSIDE PREPARATION COMPRISING ENZYMES - A hydrolytic enzyme is to be stabilized in a liquid surfactant preparation. This is achieved by using a component that stabilizes the hydrolytic enzyme and encompasses a phthaloylglutamic acid and/or a phthaloylaspartic acid. | 06-06-2013 |
20130143299 | RNF8-FHA DOMAIN-MODIFIED PROTEIN AND METHOD OF PRODUCING THE SAME - Provided is an antigen-binding protein prepared merely by a method of in vitro selection using the RNF8-FHA domain, which has no intramolecular disulfide bond and functions in cells as it is. One to four loops extending from the FHA domain are randomized, and a recognition site for a target molecule is artificially created on the FHA domain surface to construct an RNF8-FHA domain library. Using the library, an antigen-binding protein is efficiently selected in vitro. | 06-06-2013 |
20130157337 | TEMPLATE-DIRECTED ASSEMBLY OF RECEPTOR SIGNALING COMPLEXES - Transmembrane receptors in the signaling pathways of bacterial chemotaxis systems influence cell motility by forming noncovalent complexes with the cytoplasmic signaling proteins to regulate their activity. The requirements for receptor-mediated activation of CheA, the principal kinase of the | 06-20-2013 |
20130157338 | RHAMM BINDING PEPTIDES - The present invention provides for peptides that bind to Receptor for Hyaluronic Acid Mediated Motility (RHAMM) molecules. More specifically, provided are peptides capable of specifically binding RHAMM molecules and capable of binding RHAMM with substantially high affinity. These novel RHAMM-binding peptides provide the basis for new imaging probes that can be used to identify cells expressing RHAMM, and for methods of imaging, prognosis, diagnosis and treatment of conditions associated with RHAMM expression. | 06-20-2013 |
20130157339 | STABILIZED PROTEASE COMPOSITION - A composition is provided, which comprises a serine protease; a reversible inhibitor of said serine protease; and a stabilizing agent M having the formula I: | 06-20-2013 |
20130164816 | Methods and Compositions for Generating Bioactive Assemblies of Increased Complexity and Uses - The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition. | 06-27-2013 |
20130164817 | POLYPEPTIDES HAVING NUCLEIC ACID BINDING ACTIVITY - Polynucleotides having nucleic acid binding activity are provided. Methods of stabilizing a nucleic acid duplex are provided. Methods of promoting the annealing of complementary nucleic acid strands are provided. Methods of increasing the processivity of a DNA polymerase are provided. Methods of enhancing the activity of a nucleic acid modification enzyme are provided. Fusion proteins are provided. Methods of using fusion proteins are provided. Kits are provided. | 06-27-2013 |
20130171714 | PURO-DHFR QUADRIFUNCTIONAL MARKER AND ITS USE IN PROTEIN PRODUCTION - This invention relates to industrial production of proteins. More specifically, the invention relates to the res-DHFR surrogate marker, which corresponds to a fusion between DHFR and a protein conferring resistance to a toxic compound or conferring a metabolic advantage. The invention further relates to the use of res-DHFR for screening cells for high expression of a protein of interest. The invention is illustrated by the Puro-DHFR surrogate marker, which corresponds to a fusion between the puromycin N-acetyltransferase and dihydrofolate reductase (DHFR). | 07-04-2013 |
20130171715 | Phenyl Xanthene Dyes - Fluorescent phenyl xanthene dyes are described that comprise any fluorescein, rhodamine or rhodol comprising a particular C9 phenyl ring. One or both of the ortho groups on the lower C9 phenyl ring is ortho substituted with a group selected from alkyl, heteroalkyl, alkoxy, halo, haloalkyl, amino, mercapto, alkylthio, cyano, isocyano, cyanato, mercaptocyanato, nitroso, nitro, azido, sulfeno, sulfinyl, and sulfino. In one embodiment, halo and/or hydroxy groups are used. Optimal dyes contain a lower C9 phenyl ring in which both ortho groups are the same and the lower ring exhibits some form a symmetry relative to an imaginary axis running from the phenyl rings point of attachment to the remainder of the xanthene dye through a point para to the point of attachment. The phenyl xanthene dyes may be activated. Furthermore, the phenyl xanthene dyes may be conjugated to one or more substances including other dyes. The phenyl xanthene dyes are useful for a number of purposes, including labels for use in automated DNA sequencing as well the formation of fluorescent “bar codes” for polymeric particles used in the multiplexed analysis of analytes. | 07-04-2013 |
20130177960 | METHODS AND COMPOSITIONS FOR REGULATION OF TRANSGENE EXPRESSION - Nucleases and methods of using these nucleases for expressing a transgene from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom. | 07-11-2013 |
20130177961 | MULTI-ARMED, MONOFUNCTIONAL, AND HYDROLYTICALLY STABLE DERIVATIVES OF POLY(ETHYLENE GLYCOL) AND RELATED POLYMERS FOR MODIFICATION OF SURFACES AND MOLECULES - Multi-armed, monofunctional, and hydrolytically stable polymers are described having the structure | 07-11-2013 |
20130189756 | CHEMICALLY MODIFIED CARBONIC ANHYDRASES USEFUL IN CARBON CAPTURE SYSTEMS - The present disclosure relates to chemically modified carbonic anhydrase polypeptides and soluble compositions, homogenous liquid formulations comprising them. The chemically modified carbonic anhydrase polypeptides have improved properties relative to the same carbonic anhydrase polypeptide that is not chemically modified including the improved properties of increased activity and/or stability in the presence of amine compounds, ammonia, or carbonate ion. The present disclosure also provides methods of preparing the chemically modified polypeptides and methods of using the chemically modified polypeptides for accelerating the absorption of carbon dioxide from a gas stream into a solution as well as for the release of the absorbed carbon dioxide for further treatment and/or sequestering. | 07-25-2013 |
20130189757 | AFFINITY PURIFICATION OF RNA UNDER NATIVE CONDITIONS BASED ON THE LAMBDA BOXB/N PEPTIDE INTERACTION - Reagents, methods, constructs and kits are described for immobilizing or purifying a target RNA of interest, based on the interaction of boxB RNA with a bacteriophage N peptide, which in turn is linked to an immobilizing moiety capable of binding to a solid support. | 07-25-2013 |
20130196406 | NOVEL PROTEIN-POLYMER NANOCAPSULES - Disclosed are protein nanocapsules, and in particular, nanocapsules that have high thermal stability and very high resistance to thermal inactivation when subjected to steam sterilization. | 08-01-2013 |
20130196407 | Non-Leachable Magnetic Cross-Linked Enzyme Aggregate - A non-leachable, crosslinked, on a nanometer scale formed magnetic enzyme aggregate, consisting of a non-layered, hybrid nano-composite of functionalised magnetic nanoparticles and aggregated enzyme particles, is described. The magnetic enzyme aggregate can have a high enzyme content, of up to 99%. The high enzyme content allows the use on a small scale, such as for example in a fluidised bed, of the magnetic enzyme aggregate. Also, a process for the preparation of the present magnetic enzyme aggregate is described. | 08-01-2013 |
20130203148 | MODIFIED CLOSTRIDIAL TOXINS WITH ENHANCED TRANSLOCATION CAPABILITY AND ENHANCED TARGETING ACTIVITY - The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an enhanced targeting domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins. | 08-08-2013 |
20130210113 | SMALL MOLECULE DYE CONJUGATES - Chemically reactive carbocyanine dyes that are intramolecularly crosslinked between the 1-position and 3′-position, their bioconjugates and their uses are described. 1,3′-crosslinked carbocyanines are superior to those of conjugates of spectrally similar 1,1′-crosslinked or non-crosslinked dyes. The invention includes derivative compounds having one or more benzo nitrogens. | 08-15-2013 |
20130210114 | SYNTHETIC CHLOROPLAST TRANSIT PEPTIDES - This disclosure concerns compositions and methods for targeting peptides, polypeptides, and proteins to plastids of plastid-containing cells. In some embodiments, the disclosure concerns chloroplast transit peptides that may direct a polypeptide to a plastid, and nucleic acid molecules encoding the same. In some embodiments, the disclosure concerns methods for producing a transgenic plant material (e.g., a transgenic plant) comprising a chloroplast transit peptide, as well as plant materials produced by such methods, and plant commodity products produced therefrom. | 08-15-2013 |
20130210115 | Method for Activating Catalyst Using Photothermal Nanomaterials - Disclosed is a method for activating a catalyst using the photothermal effects of photothermal nanomaterials, and more particularly to a method of activating a catalyst at a temperature, at which the catalyst has low or no activity, by irradiating a catalyst-photothermal nanomaterial composite with light. The method can activate the catalyst by increasing only the temperature around the nanomaterials without substantially changing the temperature of the reaction medium. A catalyst that generally has high activity at room temperature can be activated even at low temperature. Catalysts having high activity only under mild conditions are immobilized on photothermal nanomaterials so that they have activity even under low temperature and extreme conditions. The invention is useful when a catalyst substrate unstable at room temperature is used or a catalytic product unstable at room temperature is produced. | 08-15-2013 |
20130210116 | COMPOSITION AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 08-15-2013 |
20130210117 | CRYSTALS OF MEMBRANE PROTEINS - A polypeptide in crystalline form comprises a G-protein coupled receptor (GPCR) with an IC3 loop substituted by an amino acid residue sequence of lysozyme. | 08-15-2013 |
20130217090 | CRYSTAL STRUCTURE OF GLUTAMINYL CYCLASE - Novel crystal structures of human and murine glutaminyl cyclase (QC, EC 2.3.2.5), methods of preparing the crystals, as well as the use of said crystal structures for identifying inhibitors of human and murine glutaminyl cyclase. | 08-22-2013 |
20130217091 | Dimeric Alpha Interferon PEGylated Site-Specifically Shows Enhanced and Prolonged Efficacy in Vivo - The present invention concerns methods and compositions for PEGylated complexes of defined stoichiometry and structure. Preferably, the PEGylated complex is formed using dock-and-lock technology, by attaching a therapeutic agent to a DDD sequence and a PEG moiety to an AD sequence, allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two therapeutic agents and one PEG moiety. Alternatively, the therapeutic agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one therapeutic agent. In more preferred embodiments, the therapeutic agent may comprise any peptide or protein of physiologic or therapeutic activity, preferably a cytokine, more preferably interferon-α2b. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases. | 08-22-2013 |
20130224828 | RNA-Directed Packaging of Enzymes Within Protein Particles - Protein nanoparticles encapsulate cargo proteins within an enclosure containing a protected chemical milieu. Encapsulation within such protected chemical milieu enhances the employability and performance of cargo proteins, particularly cargo enzymes, particularly within otherwise hostile chemical environments. Protein nanoparticles are assembled using shell proteins, such as viral coat proteins like Qβ, in the presence of a bifunctional polynucleotide and the selected cargo protein. The bifunctional polynucleotide includes two aptameric activities that assist the disposition and retention of cargo proteins within the protein nanoparticle. | 08-29-2013 |
20130230897 | COMPLEX OF LABELED PROBES AND WATER-SOLUBLE CARRIER - The purpose is to produce, with high reproducibility, a complex of labeled probes and a carrier, said complex being to be used for detecting and measuring a target substance to be measured with high sensitivity and high stability. The means for accomplishing the purpose is that a label is bound to a probe-water soluble carrier conjugate using specific binding of an avidin compound such as avidin, streptavidin, etc. to biotin, and the binding of the avidin compound to the probe is performed before the binding to the carrier. Namely, after conjugating the avidin compound to a substance which is capable of binding to the target substance, the conjugate is bound to a high-molecule water-soluble carrier to produce a complex of the avidinized probes and the water-soluble carrier. Then the complex of the avidinized probes and the water-soluble carrier is mixed with a biotinylated label. Thus, a stable complex of the labeled probes and the water-soluble carrier, which enables the highly sensitive detection and measurement of the target substance, can be obtained with high reproducibility via the specific binding of the avidin compound to biotin. | 09-05-2013 |
20130230898 | HYDROXYALKYL STARCH DERIVATIVES AND PROCESS FOR THEIR PREPARATION - The invention relates to a method for the preparation of a hydroxyalkyl starch derivative which comprises reacting hydroxyalkyl starch (HAS) via the optionally oxidised reducing end of the HAS with the amino group M of a crosslinking compound which, apart from the amino group, comprises a specifically protected carbonyl group, namely an acetal group or a ketal group. | 09-05-2013 |
20130230899 | THERAPEUTIC AGENT FOR ARTERIOSCLEROSIS OR ARTERIOSCLEROTIC DISEASE, AND DIAGNOSTIC AGENT FOR ARTERIOSCLEROSIS OR ARTERIOSCLEROTIC DISEASE - It is intended to ameliorate arteriosclerosis or arteriosclerotic disease through a pharmacological mechanism that reduces the size of the arteriosclerotic lesion. The agent of the present invention comprises a complex comprising an antibody binding to folate receptor β (FRβ) and a cytotoxin or a cytotoxic agent conjugated with the antibody, or the antibody as an active ingredient. | 09-05-2013 |
20130236945 | Fusion Protein Having Factor VII Activity - A fusion protein comprising factor VII (FVII) and transferrin according to the present invention has an improved specific activity of FVII compared to existing FVII fusion proteins comprising other fusion partners than transferrin, and thus can be effectively used in a therapy using FVII. | 09-12-2013 |
20130252306 | METHODS FOR INCREASING PROTEIN POLYETHYLENE GLYCOL (PEG) CONJUGATION - The present invention relates to highly conjugated proteins and methods for making such proteins. In particular, the present invention relates to methods for linking additional sites to a protein for conjugation with activated polyethylene glycol (PEG) linkers, without denaturing the protein. The invention also relates to highly conjugated proteins with decreased immunogenicity and increased circulating half-life. | 09-26-2013 |
20130280782 | PROTEIN-BASED CONJUGATES AND SELF-ASSEMBLED NANOSTRUCTURES - The present disclosure provides protein-containing compositions, methods and uses thereof. A conjugate comprises a globular protein conjugated with a polymer that preserves the folded and functional structure of a protein. In some embodiments, a fusion protein comprises a globular protein conjugated with an elastin-mimic polymer (EMP). Also disclosed is an assembled solid-state or gel-state nanostructure comprising a plurality of conjugates, wherein each comprises a globular protein conjugated with a polymer that preserving the folded and functional structure of a protein. In certain embodiments, provided compositions and methods further comprise an additive. | 10-24-2013 |
20130280783 | POLYMERIC ALPHA-HYDROXY ALDEHYDE AND KETONE REAGENTS AND CONJUGATION METHOD - Provided herein are polymeric α-hydroxy aldehyde or α-hydroxy ketone reagents which can be conjugated to amine-containing compounds to form stable conjugates in a single-step reaction. In selected embodiments, the polymeric reagent itself incorporates an internal proton-abstracting (basic) functional group, to promote more efficient reaction. The substituent is appropriately situated, via a linker if necessary, to position the group for proton abstraction, preferably providing a 4- or 5-bond spacing between the abstracting atom and the hydrogen atom on the α-carbon. Also provided are methods of using the reagents and stable, solubilized conjugates of the reagents with biologically active compounds. In preferred embodiments, the polymeric component of the reagent or conjugate is a polyethylene glycol. | 10-24-2013 |
20130288333 | PROTEIN COMPLEX USING AN IMMUNOGLOBULIN FRAGMENT AND METHOD FOR THE PREPARATION THEREOF - Disclosed are a protein conjugate with improved in vivo duration and stability and the use thereof. The protein conjugate includes a physiologically active polypeptide, a non-peptide polymer and an immunoglobulin Fc fragment. Since the three components are covalently linked, the protein conjugate has extended in vivo duration and enhanced stability for the physiologically active polypeptide. The protein conjugate maintains the in vivo activity at relatively high levels and remarkably increases the serum half-life for the physiologically active polypeptide, with less risk of inducing undesirable immune responses. Thus, the protein conjugate is useful for developing long-acting formulations of various polypeptide drugs. | 10-31-2013 |
20130288334 | DEGRADABLE CLOSTRIDIAL TOXINS - The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras. | 10-31-2013 |
20130295638 | SYNTHETIC BRASSICA-DERIVED CHLOROPLAST TRANSIT PEPTIDES - This disclosure concerns compositions and methods for targeting peptides, polypeptides, and proteins to plastids of plastid-containing cells. In some embodiments, the disclosure concerns chloroplast transit peptides that may direct a polypeptide to a plastid, and nucleic acid molecules encoding the same. In some embodiments, the disclosure concerns methods for producing a transgenic plant material (e.g., a transgenic plant) comprising a chloroplast transit peptide, as well as plant materials produced by such methods, and plant commodity products produced therefrom. | 11-07-2013 |
20130295639 | Branched Polymers - The present invention is directed to branched reactive water-soluble polymers comprising at least two polymer arms, such as poly(ethylene glycol), attached to a central aliphatic hydrocarbon core molecule through heteroatom linkages. The branched polymers bear at least one functional group for reacting with a biologically active agent to form a biologically active conjugate. The functional group of the branched polymer can be directly attached to the aliphatic hydrocarbon core or via an intervening linkage, such as a heteroatom, -alkylene-, —O-alkylene-O—, -alkylene-O-alkylene-, -aryl-O—, —O-aryl-, (—O-alkylene-) | 11-07-2013 |
20130295640 | Methods and Reagents for Preparing Multifunctional Probes - Multifunctional probes are synthesized in a single step using peptide scaffold-based multifunctional single-attachment-point reagents. To obtain multifunctional probes of the invention, a substrate (e.g., a nanoparticle, polymer, antibody, protein, low molecular weight compound, drug, etc.) is reacted with a multifunctional single-attachment-point (MSAP) reagent. The MSAP reagents can include three components: (i) a peptide scaffold, (ii) a single chemically reactive group on the peptide scaffold for reaction of the MSAP with a substrate having a complementary reactive group, and (iii) multiple functional groups on the peptide scaffold. The peptide scaffold can include any number of residues; however, for ease of synthesis and reproducibility in clinical trials, it is preferred to limit the residues in the peptide to 20 or less. The reagent can be prepared to yield a predetermined stoichiometric ratio of the functional groups on the scaffold such that the probe has a fixed stoichiometric ratio of the functional groups. | 11-07-2013 |
20130295641 | Production of Conjugates - A method of reacting a first chemical entity and a second chemical entity to form a conjugate in which the first and second chemical entities are covalently bound with respect to each other, comprises bringing into simultaneous contact the first chemical entity, the second chemical entity and a thiol generator, wherein the thiol generator reacts with the first chemical entity in a thiolation reaction resulting in formation of a free sulfhydryl group on the first chemical entity, and the free sulfhydryl group reacts with the second chemical entity to form the conjugate, and wherein the second chemical entity is polyvalent with respect to its reactivity with sulfhydryl groups. The present invention primarily differs from the prior art in that no separation step is involved between reaction of the thiol generator and first chemical entity and reaction with the second chemical entity. The invention also provides a conjugation kit. | 11-07-2013 |
20130295642 | PROTEIN COMPLEX HAVING ACTIVITY CATALYZING ASYMMETRIC OXIDATION REACTION AND PROCESS FOR PRODUCING THE SAME - A process for producing a cross-linked crystallized protein complex, which comprises: a first step of concentrating a crude protein derived from an animal or plant; a second step of encapsulating the protein in a gel, to thereby allow the protein to undergo air oxidation, and then extracting a protein complex from the gel; a third step of allowing the extracted protein complex to undergo crystallization and precipitation; and a fourth step of cross-linking the precipitated protein complex. Alternatively, by use of a fifth step of drying (FD) the obtained crosslinked crystallized protein complex, to thereby form a powder. As a result, there is provided an enzyme which is stable at room temperature storage, and has an activity in catalyzing an asymmetric oxidation reaction. That is, there is provided a useful material which enables an efficient enzyme-mimetic reaction under a mild condition. | 11-07-2013 |
20130295643 | NON-CYTOTOXIC PROTEIN CONJUGATES - The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a dynorphin Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are also described. | 11-07-2013 |
20130302876 | Transducible Polypeptides For Modifying Metabolism - Methods and compositions for modifying the metabolism of a subject are provided. One embodiment provides a recombinant polypeptide having a polynucleotide-binding domain, a protein transduction domain, and a targeting domain. In a preferred embodiment, the polynucleotide-binding domain includes one or more HMG box domains. | 11-14-2013 |
20130302877 | Differential Functionalization of Polymers with Amino-Oxy Reagents for Diagnostic Assays - This invention relates to a method of conveniently functionalizing the reducing end of a carbohydrate polymer. The method also allows for the length of the polymer to be differentially functionalized. The invention provides a method for preparing polymers with a different functional groups or functionality on the sides than on the reducing end. An advantage of the method of the invention is that the procedures are simpler, preferably requiring less time, fewer steps, reduced temperatures and less harsh chemical components than conventional procedures for differential modification, with the further advantage that the reactions can be carried out in aqueous media. | 11-14-2013 |
20130309747 | MGMT-BASED METHOD FOR OBTAINING HIGH YEILDS OF RECOMBINANT PROTEIN EXPRESSION - The present invention relates to a novel enhancer of protein production in host cells. It discloses a vector for expressing recombinant proteins in these cells, comprising a nucleotide sequence encoding a) a secretion peptidic signal, b) a 6-methylguanine-DNA-methyltransferase enzyme (MGMT, EC 2.1.1.63), a mutant or a catalytic domain thereof, and c) a recombinant protein. Said MGMT enzyme is preferably the so-called SNAP protein. | 11-21-2013 |
20130309748 | ENZYMATIC CONVERSION OF VOLATILE ORGANIC COMPOUNDS - The present invention relates to a composition comprising a stable aqueous dispersion of polymer particles, an oxidoreductase, and a cofactor for the oxidoreductase and a method for its preparation. The invention is useful for converting certain classes of VOCs to non-VOCs. | 11-21-2013 |
20130323812 | IN SITU RESTORATION OF APATITE-BASED CHROMATOGRAPHY RESINS - Methods and compositions are provided for treatment of an apatite-based resin from which retained solutes have been eluted by an elution buffer that contains an alkali metal salt with solutions of calcium ion, phosphate ion, and hydroxide separately from any sample loading and elution buffers. The treatment solutions restore the resin, reversing the deterioration that is caused by the alkali metal salt in the elution buffer. | 12-05-2013 |
20130323813 | PEPTIDES FOR THE SPECIFIC BINDING OF RNA TARGETS - A recombinant polypeptide is described including at least one PUF RNA-binding domain capable of specifically binding to a cytosine RNA base. The PUF RNA-binding domain of the polypeptide includes at least one RNA base-binding motif of the general formula X | 12-05-2013 |
20130330802 | METHOD FOR PRODUCTION OF RECOMBINANT HUMAN IDURONATE 2-SULFATASE - Disclosed is a method for production of recombinant human iduronate 2-sulfatase (rhI2S) in a large scale, with a high purity, and mannose 6-phosphate residues. The method comprises the steps of (a) culturing rhI2S-producing mammalian cells in a serum-free medium, (b) collecting culture supernatant, (c) subjecting the culture supernatant to cation-exchange column chromatography, (d) to dye affinity column chromatography, (e) to anion-exchange column chromatography, and (f) to a column chromatography employing as solid phase a material having affinity for phosphate group, and (g) to gel filtration column chromatography, in the order. | 12-12-2013 |
20130337532 | THERAPEUTIC POLYPEPTIDES WITH INCREASED IN VIVO RECOVERY - The present invention relates to the field of modified therapeutic polypeptides with increased in vivo recovery compared to their non-modified parent polypeptide. For example, the invention relates to fusions of therapeutic polypeptides with recovery enhancing polypeptides connected directly or optionally connected by a linker peptide. | 12-19-2013 |
20130337533 | Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondins) and/or Wnt - The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4(=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein. | 12-19-2013 |
20130337534 | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates And Their Preparation - The present invention relates to polymeric reagents and conjugates thereof, methods for synthesizing the polymeric reagents and conjugates, pharmaceutical compositions comprising the conjugates and methods of using the polymer conjugates including therapeutic methods where conjugates are administered to patients. | 12-19-2013 |
20130337535 | Control of Cyanate in Aqueous Urea Solutions by Non-1,2-Ethylene Diamine Like Compounds for the Protection of Protein/Peptide Carbamylation - Embodiments of the present invention generally relate to processing of peptides in urea solutions and substantial prevention of carbamylation of the peptide. | 12-19-2013 |
20130337536 | Labeling Reagents and Methods of Their Use - The present disclosure is directed to a reactive ester agent capable of conjugating a reporter molecule to a carrier molecule or solid support. The reactive ester agent has the general formula: | 12-19-2013 |
20130337537 | COAGULATION FACTOR-TARGETING TO TLT-1 ON ACTIVATED PLATELETS - The current invention relates to: procoagulant proteins which may, for example, be fusion proteins or chemical conjugates; methods of producing said procoagulant proteins; polynucleotides that encode said fusion proteins and cells that expresses them. Furthermore, the current invention relates to procoagulant proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with the procoagulant proteins of the current invention. | 12-19-2013 |
20140004591 | SITE SPECIFICALLY INCORPORATED INITIATOR FOR GROWTH OF POLYMERS FROM PROTEINS | 01-02-2014 |
20140004592 | Dendrimer-Based Excipients for the Attenuation of Protein Aggregation | 01-02-2014 |
20140011255 | Biotin Derivatives - Biotin derivatives, methods of using the biotin derivatives and kits comprising the biotin derivatives. | 01-09-2014 |
20140017763 | PERFORMANCE-ENHANCED PROTEASE VARIANTS - Proteases encompassing an amino acid sequence, which are at least 70% identical to the amino acid sequence specified in SEQ ID NO. 1 over the entire length thereof and which, in the listing according to SEQ ID NO. 1, have the amino acid substitution I21V in combination with at least one further amino acid substitution, the further amino acid substitution being selected from the group consisting of Q12L, M122L, N177V, A222S, V228I and T247N, and agents encompassing such proteases, exhibit very good cleaning performance on egg-containing stains. | 01-16-2014 |
20140030789 | Producing Dicarboxylic Acids Using Polyketide Synthases - The present invention provides for a polyketide synthase (PKS) capable of synthesizing a dicarboxylic acid (diacid). Such diacids include diketide-diacids and triketide-diacids. The invention includes recombinant nucleic acid encoding the PKS, and host cells comprising the PKS. The invention also includes methods for producing the diacids. | 01-30-2014 |
20140038261 | Compositions and Methods of Use of Immunotoxins Comprising Ranpirnase (Rap) Show Potent Cytotoxic Activity - The present invention concerns methods and compositions for forming immunotoxin complexes having a high efficacy and low systemic toxicity. In preferred embodiments, the toxin moiety is a ranpirnase (Rap), such as Rap(Q). In more preferred embodiments, the immunotoxin is made using dock-and-lock (DNL) technology. The immunotoxin exhibits improved pharmacokinetics, with a longer serum half-life and significantly greater efficacy compared to toxin alone, antibody alone, unconjugated toxin plus antibody or even other types of toxin-antibody constructs. In a most preferred embodiment the construct comprises an anti-Trop-2 antibody conjugated to Rap, although other combinations of antibodies, antibody fragments and toxins may be used to form the subject immunotoxins. The immunotoxins are of use to treat a variety of diseases, such as cancer, autoimmune disease or immune dysfunction. | 02-06-2014 |
20140045242 | Novel Strategies for Improved Cancer Vaccines - The present invention concerns methods and compositions for forming anti-cancer vaccine complexes. In preferred embodiments, the anti-cancer vaccine complex comprises an antibody moiety that binds to dendritic cells, such as an anti-CD74 antibody or antigen-binding fragment thereof, attached to an AD (anchoring domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety, resulting in the formation of the vaccine complex. The anti-cancer vaccine complex is capable of inducing an immune response against xenoantigen expressing cancer cells, such as CD138 | 02-13-2014 |
20140051145 | NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS - The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof. | 02-20-2014 |
20140073029 | TARGETED PERHYDROLASES - Disclosed herein are compositions and methods to target enzymatic peracid production to a target surface. The peracid benefit agent produced by the targeted perhydrolytic enzyme can be use for a variety of applications such as bleaching, whitening, disinfecting, destaining, deodorizing, and combinations thereof. Specifically, a fusion protein comprising a perhydrolytic enzyme and at least one peptidic component having affinity for a target surface (excluding body surfaces and oral care surfaces) is used in combination with a suitable substrate and a source of peroxygen to enzymatically produce a peracid on or near the surface of the target material. In a preferred aspect, the target surface is a cellulosic material. | 03-13-2014 |
20140073030 | DETERGENT COMPOSITIONS CONTAINING BACILLUS AGARADHAERENS MANNANASE AND METHODS OF USE THEREOF - The present compositions and methods relate to an endo-β-mannanase cloned from | 03-13-2014 |
20140080198 | MOLECULAR ZIPPER TWEEZERS AND SPRING DEVICES - Techniques, structures, devices and systems are disclosed for implementing molecular zipper tweezers and springs. In one aspect, a molecular device includes three molecular components including at least a passive side molecular component, a binding side molecular component and a target molecular component adapted to interact together as a zipper that separate two of the molecular components held together by molecular interaction forces. | 03-20-2014 |
20140087441 | NOVEL APPLICATION OF FIBRINOGEN-420 AND ITS ACTIVE DOMAIN - The invention discloses a novel application of fibrinogen-420 and its active domain (alpha EC domain), and a separate alpha EC domain protein has the same or similar function with fibrinogen-420. Fibrinogen-420 and its active domain can be widely used in inhibiting protein aggregation, helping protein refolding, drugs which can prevent and/or treat protein conformation disease, detecting denatured protein in quality control and protect protein from denaturation. | 03-27-2014 |
20140093935 | CHARGED TRIPLET-STATE QUENCHERS FOR MITIGATION OF PHOTO-INDUCED DAMAGE - Mitigation of photo-induced damage in excitation illuminated reactions and analyses utilizing such reactions results in an enhanced performance for the reactions and the analyses. There is provided a novel class of triplet-state quenchers for mitigating photo-induced damage which are both simple in structure and effective at preventing and/or reducing photo-induced damage to reaction components of excitation illuminated reaction mixtures. Also provided are methods of using the compounds of the invention, devices and kits incorporating the compounds of the invention. | 04-03-2014 |
20140099696 | Technology for the Preparation of Microparticles - Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions. | 04-10-2014 |
20140099697 | METHOD FOR PREVENTING THE UNFOLDING OF A (POLY)PEPTIDE AND/OR INDUCING THE (RE-)FOLDING OF A (POLY)PEPTIDE - The present invention relates to a method for preventing the unfolding of a (poly)peptide during drying and/or inducing the (re-)folding of a (poly)peptide after drying, comprising the step of embedding the (poly)peptide in an aqueous solution, wherein the solution comprises (i) at least three different amino acids; or (ii) at least one dipeptide or tripeptide; and wherein the solution is free or substantially free of (a) sugar; and (b-i) protein; and/or (b-ii) denaturing compounds; and (c) silanes. | 04-10-2014 |
20140106433 | RNase H-Based Assays Utilizing Modified RNA Monomers - The present invention pertains to novel oligonucleotide compounds for use in various biological assays, such as nucleic acid amplification, ligation and sequencing reactions. The novel oligonucleotides comprise a ribonucleic acid domain and a blocking group at or near the 3′ end of the oligonucleotide. These compounds offer an added level of specificity previously unseen. Methods for performing nucleic acid amplification, ligation and sequencing are also provided. Additionally, kits containing the oligonucleotides are also disclosed herein. | 04-17-2014 |
20140113348 | MEDITOPES AND MEDITOPE-BINDING ANTIBODIES AND USES THEREOF - Antibodies and meditopes that bind to the antibodies are provided, as well as complexes, compositions and combinations containing the meditopes and antibodies, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses. | 04-24-2014 |
20140113349 | Solubilized Phospholipids for Stabilizing Nucleic Acid Polymerases - Compositions and methods are provided that relate to solubilized phospholipids and their use in stabilizing nucleic acid polymerases. For example, a phospholipid with a tail containing at least 8 carbons can be solubilized in the presence of an amphipathic molecule. | 04-24-2014 |
20140127777 | METHOD FOR STABILIZATION OF PROTEINS USING NON-NATURAL AMINO ACIDS - The present invention provides a method for producing modified stable polypeptides introducing at least one non-natural amino acid into the hydrophobic region of the polypeptide. The thermal and chemical stability of such polypeptides is improved compared to those properties of its corresponding wild type proteins. | 05-08-2014 |
20140127778 | MANUFACTURING METHOD FOR SILICA ENCAPSULATED SINGLE-ENZYME NANOPARTICLES AND SINGLE-ENZYME NANOPARTICLES MANUFACTURED BY MEANS OF METHOD - A method for manufacturing single enzyme nanoparticles through silica encapsulation according to the present disclosure does not include a surface functionalization process and a polymerization process during the synthesis, and reaction conditions are mild. Thus, the method is appropriate for a large scale production. | 05-08-2014 |
20140127779 | Fractionation of Charged Polysaccharide - Polydisperse and charged polysaccharides are fractionated into low polydispersity fractions (preferably having pd<1.1), each containing species within a narrow range of molecular weights. An aqueous solution of the polydisperse polysaccharides is contacted with an ion exchange resin in a column and the polysaccharides are subjected to selective elution by aqueous elution buffer. The selective elution consists of at least 3 sequential elution buffers having different and constant ionic strength and/or pH and in which the subsequent buffers have ionic strength and/or pH than those of the preceding step. The new preparations are particularly suitable for the production of PSA-derivatised therapeutic agents intended for use in humans and animals. | 05-08-2014 |
20140134702 | Solubilized Phospholipids for Stabilizing Nucleic Acid Polymerases - Compositions and methods are provided that relate to solubilized phospholipids and their use in stabilizing nucleic acid polymerases. For example, a phospholipid with a tail containing at least 8 carbons can be solubilized in the presence of an amphipathic molecule. | 05-15-2014 |
20140134703 | Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondins) and/or Wnt - The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4 (=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein. | 05-15-2014 |
20140141483 | POLYMER FACTOR IX MOIETY CONJUGATES - Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is polyethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the conjugates. | 05-22-2014 |
20140141484 | Multiple Hybrid Immunoassay - The invention relates to compositions and methods for the immunoassay of an analyte of interest. The analyte is detected in an immunoassay using three or more antibodies, wherein each antibody specifically binds to a different epitope on the analyte. When the analyte of interest in a clinical marker for an acute disease, the detection of the analyte by immunoassay is a diagnosis of the occurrence of the disease. | 05-22-2014 |
20140141485 | ZCYTOR17 HETERODIMERIC CYTOKINE RECEPTOR - Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto. | 05-22-2014 |
20140141486 | Activated Sialic Acid Derivatives For Protein Derivatisation And Conjugation - Derivatives of PSAs are synthesised, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems. | 05-22-2014 |
20140141487 | Cationic Polymer Based Wired Enzyme Formulations for Use in Analyte Sensors - Embodiments of the invention include analyte-responsive compositions and electrochemical analyte sensors having a sensing layer that includes an analyte-responsive enzyme and a cationic polymer. Also provided are systems and methods of making the sensors and using the electrochemical analyte sensors in analyte monitoring. | 05-22-2014 |
20140147906 | ANTIBODY CONJUGATES - Antibody/signal-generating moiety conjugates are disclosed that include an antibody covalently linked to a signal-generating moiety through a heterobifunctional polyalkyleneglycol linker. The disclosed conjugates show exceptional signal-generation in immunohistochemical and in situ hybridization assays on tissue sections and cytology samples. In one embodiment, enzyme-metallographic detection of nucleic acid sequences with hapten-labeled probes can be accomplished using the disclosed conjugates as a primary antibody without amplification. | 05-29-2014 |
20140154773 | THROMBIN SOLUTION AND METHODS OF USE THEREOF - Provided are methods for lyophilization of an aqueous thrombin solution, thrombin solutions for use in such lyophilization methods, and solid thrombin compositions produced by such methods. | 06-05-2014 |
20140154774 | NPP1 FUSION PROTEINS - The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide. | 06-05-2014 |
20140154775 | PHOTOCLEAVABLE LINKER - There are provided, inter alia, photolabile compounds and methods useful for the formation of dimers of biological molecules and subsequent dissociation of the dimers. | 06-05-2014 |
20140154776 | Stable Lysis Buffer Mixture for Extracting Nucleic Acids - Embodiments relate to a lysis buffer mixture that is stable in storage for isolating nucleic acids from biological, preferably diagnostic samples. The mixture is preferably associated with an extraction control. The aim of the invention is to provide an improved nucleic acid extraction system, which is cost-effective, stable and easy to use, thus fulfilling the requirements of a modern nucleic acid extraction system and containing, among other things, extraction controls. Embodiments relate to a lysis buffer mixture for isolating nucleic acids, said mixture containing non chaotropic salts, a special selection of detergents, a defined quantity of at least one nucleic acid as an extraction control, optionally lytic enzymes, optionally carrier nucleic acids and optionally other additives. | 06-05-2014 |
20140162339 | Stabilized Compounds Having Secondary Structure Motifs - The present invention provides novel stabilized crosslinked compounds having secondary structure motifs, libraries of these novel compounds, and methods for the synthesis of these compounds libraries thereof. The synthesis of these novel stabilized compounds involves (1) synthesizing a peptide from a selected number of natural or non-natural amino acids, wherein said peptide comprises at least two moieties capable of undergoing reaction to promote carbon-carbon bond formation; and (2) contacting said peptide with a reagent to generate at least one crosslinker and to effect stabilization of a secondary structure motif. The present invention, in a preferred embodiment, provides stabilized p53 donor helical peptides. Additionally, the present invention provides methods for disrupting the p53/MDM2 binding interaction comprising (1) providing a crosslinked stabilized α-helical structure; and (2) contacting said crosslinked stabilized α-helical structure with MDM2. | 06-12-2014 |
20140162340 | SYNTHETIC HEPATITIS C GENOME AND METHODS OF MAKING AND USE - Synthetic representative HCV subtypes, including a 1a and 1b genome, dubbed Bole1a and Bole1b, are provided using an inventive method of Bayesian phylogenetic tree analysis, ancestral sequence reconstruction and covariance analysis. Bole1a branches centrally among 390 full-genome sequences used in its design, a carefully curated 143 sequence full-genome dataset, and separate genomic regions including an independent set of 214 E1E2 sequences from a Baltimore cohort. Bole1a is phylogenetically representative of widely circulating strains. Full genome non-synonymous diversity comparison and 9-mer peptide coverage analysis showed that Bole1a is able to provide more coverage (94% and 78% respectively) than any other sequence in the dataset including H77, a traditional reference sequence. Bole1a also provides unsurpassed epitope coverage when compared to all known T cell epitopes. | 06-12-2014 |
20140170728 | Factor IX: Remodeling and Glycoconjugation of Factor IX - The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide. | 06-19-2014 |
20140170729 | SSO7-POLYMERASE CONJUGATES WITH DECREASED NON-SPECIFIC ACTIVITY - Improved Sso7-polymerase conjugate proteins are provided. | 06-19-2014 |
20140186917 | Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondins) and/or Wnt - The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4(=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein. | 07-03-2014 |
20140193874 | NOVEL BIOMARKER FOR DIAGNOSIS OF LUNG CANCER - Disclosed are a composition for diagnosis of lung cancer including an antibody specific to GPI specific phospholipase D1 (GPLD1) protein, which is an effective biomarker for early diagnosis of lung cancer, and a composition for diagnosis of lung cancer including a primer or probe specific to a nucleic acid encoding the GPLD1 protein. The lung cancer diagnostic marker may be effectively used in early diagnosis of lung cancer and also, is very useful for evaluating progression of a disease and prognosis before and after treatment of the same. | 07-10-2014 |
20140193875 | POROUS POLYMERIC RESINS - Porous polymeric resins, reaction mixtures and methods that can be used to prepare the porous polymeric resins, and uses of the porous polymeric resin are described. More specifically, the polymeric resins typically have a hierarchical porous structure plus reactive groups that can be used to interact with or react with a variety of different target compounds. The reactive groups can be selected from an acidic group or a salt thereof, an amino group or salt thereof, a hydroxyl group, an azlactone group, a glycidyl group, or a combination thereof. | 07-10-2014 |
20140199749 | Compositions and Methods for cDNA Synthesis - The present invention relates to methods and compositions for preparing cDNAs, and more particularly, compositions having trehalose for synthesizing a cDNA molecule or molecules from an mRNA template or population of mRNA templates under conditions sufficient to increase the detection sensitivity and cDNA yield and to simplify and improve the reliability of reverse transcription. The reagent mixture comprises a ready to use reagent solution, wherein the solution comprises: (a) trehalose in a concentration between about 5% and about 35%; and (b) a viral reverse transcriptase selected from the group consisting of AMV RT, RSV RT, MMLV RT, HIV RT, EIAV RT, RAV2 RT, ASLV RT, RNaseH (−) RT, SuperScript II RT, and ThermoScript RT, in a buffer suitable for use in a reverse transcription reaction, wherein the buffer further comprises a co-factor metal ion and nucleoside triphosphates. | 07-17-2014 |
20140199750 | MONOFUNCTIONAL BRANCHED POLYETHYLENE GLYCOL AND MODIFIED BIO-RELATED SUBSTANCE THEREOF - The monofunctional branched poly(ethylene glycol) (PEG) has a general formula shown in formula (1), and the bio-related substance modified by the monofunctional branched PEG has a general fomula shown in formula (2), wherein X | 07-17-2014 |
20140206061 | BIOACTIVE CARBON NANOTUBE COMPOSITE FUNCTIONALIZED WITH B-SHEET POLYPEPTIDE BLOCK COPOLYMER, AND PREPARATION METHOD THEREOF - The present invention relates to a bioactive carbon nanotube composite functionalized with a β-sheet polypeptide block copolymer by combination self-assembly, which shows excellent water dispersion, and has biological activity so as to be used as stimulus-responsive and adaptable biomaterials or in the manufacture of CNT-based electronic biosensor devices. In addition, the bioactive carbon nanotube composite can be used as a composition for delivery of a biological active material into cells. Further, the application of the interaction between a β-sheet peptide and a carbon-based hydrophobic material is expected to be useful for designing and developing an inhibitor for diseases caused by the abnormal folding of a protein and by biomacromolecular interactions (protein-protein, protein-DNA, and protein-RNA interactions etc). | 07-24-2014 |
20140212945 | RNA TARGETING COMPOUNDS AND METHODS FOR MAKING AND USING SAME - Disclosed are RNA targeting compounds, methods for using the subject RNA targeting compounds to treat myotonic dystrophy and other diseases are also disclosed. | 07-31-2014 |
20140212946 | NON-NATURAL RIBONUCLEASE CONJUGATES AS CYTOTOXIC AGENTS - The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been modified to make it toxic to target cells and that can be conjugated to a target cell-specific delivery vector, such as an antibody, for delivery to pathogenic cells. | 07-31-2014 |
20140212947 | ELECTRODE INCLUDING A SELF-ASSEMBLING POLYMER HAVING AN ORGANOMETAL, AND METHOD FOR MANUFACTURING SAME - The present invention relates to a bioelectrode including a cross-linkable organometallic polymer, and to a method for manufacturing same, and more particularly, to an electrode in which a nanostructure of the organometallic polymer is controlled to be used in bio fuel cells, biosensors, and the like. The electrode according to the present invention includes an organometal and further includes a self-assembling block copolymer and enzyme, and provides usages in bio fuel cells and biosensors. | 07-31-2014 |
20140220656 | CONSTRUCTS AND METHODS FOR THE PRODUCTION AND SECRETION OF POLYPEPTIDES - Described herein are molecules, constructs and methods for the production and secretion of polypeptides of interest by host cells, preferably bacterial host cells, and more particularly gram positive bacteria. In particular, the present invention is related to a polynucleic acid encoding a fusion protein and to uses thereof for the secretion of heterologous or homologous polypeptides of interest by a bacterial host cell, preferably | 08-07-2014 |
20140242664 | ENGINEERING OF SYSTEMS, METHODS AND OPTIMIZED GUIDE COMPOSITIONS FOR SEQUENCE MANIPULATION - The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR-Cas system. | 08-28-2014 |
20140242665 | Phenyl Xanthene Dyes - Fluorescent phenyl xanthene dyes are described that comprise any fluorescein, rhodamine or rhodol comprising a particular C9 phenyl ring. One or both of the ortho groups on the lower C9 phenyl ring is ortho substituted with a group selected from alkyl, heteroalkyl, alkoxy, halo, haloalkyl, amino, mercapto, alkylthio, cyano, isocyano, cyanato, mercaptocyanato, nitroso, nitro, azido, sulfeno, sulfinyl, and sulfino. In one embodiment, halo and/or hydroxy groups are used. Optimal dyes contain a lower C9 phenyl ring in which both ortho groups are the same and the lower ring exhibits some form a symmetry relative to an imaginary axis running from the phenyl rings point of attachment to the remainder of the xanthene dye through a point para to the point of attachment. The phenyl xanthene dyes may be activated. Furthermore, the phenyl xanthene dyes may be conjugated to one or more substances including other dyes. The phenyl xanthene dyes are useful for a number of purposes, including labels for use in automated DNA sequencing as well the formation of fluorescent “bar codes” for polymeric particles used in the multiplexed analysis of analytes. | 08-28-2014 |
20140242666 | VACCINE FOR SHIGELLA - Disclosed are immunogenic conjugates and therapeutic compositions that include such immunogenic conjugates. Also disclosed are methods of treating and/or inhibiting an | 08-28-2014 |
20140248682 | HSA-RELATED COMPOSITIONS AND METHODS OF USE - Provided are human serum albumin (HSA) compositions with improved properties over native HSA. | 09-04-2014 |
20140256017 | SACCHARIDE-CONTAINING PROTEIN CONJUGATES AND USES THEREOF - Conjugates of a saccharide and a biomolecule, covalently linked therebetween via a non-hydrophobic linker and methods of preparing same are disclosed. Also disclosed are medical uses utilizing such conjugates. Glycosylation reagents for use in preparing these conjugates are also disclosed. Glycosylated proteins, characterized by improved performance, are also disclosed. | 09-11-2014 |
20140273151 | ENZYME SUBSTRATE COMPRISING A FUNCTIONAL DYE AND ASSOCIATED TECHNOLOGY AND METHODS - Enzyme substrates and associated technology of the present invention are provided. An enzyme substrate of the invention may comprise a biologically functional fluorescent dye and an enzyme-specific substrate moiety attached in such a way that the functionality of the functional dye is diminished. An enzymatic reaction may cleave at least a portion of the substrate moiety from the enzyme substrate to provide a more functional product dye. This product dye may be nonfluorescent or weakly fluorescent, in general, and relatively fluorescent, in a particular condition, such as when bound to a partner biological molecule or an assembly of partner biological molecules. An enzyme substrate of the present invention may thus be useful in fluorescence detection, and/or in any of a variety of useful applications, such as the detection of enzymatic activity in a cell-free system or in a living cell, the screening of drugs, or the diagnosis of disease. | 09-18-2014 |
20140273152 | RECOMBINANT MANGANESE OXIDASE - Disclosed herein is a recombinant | 09-18-2014 |
20140273153 | COVALENT MODIFICATION OF BIOLOGICAL MACROMOLECULES - The present disclosure provides a method of covalently modifying a biological macromolecule, the method comprising subjecting a reaction mixture comprising: (a) a biological macromolecule comprising one or more thiol groups; and (b) a molecule comprising one or more olefin or alkyne moieties to a radical reaction under conditions sufficient to produce the covalently modified biological macromolecule. The present disclosure also provides a method of covalently modifying a biological macromolecule, the method comprising subjecting a reaction mixture comprising: (a) a molecule comprising one or more thiol groups; and (b) a biological macromolecule comprising one or more olefin or alkyne moieties to a radical reaction under conditions sufficient to produce the covalently modified biological macromolecule. The present disclosure further provides a covalently modified biological macromolecule prepared by any of the disclosed methods. The covalently modified biological macromolecules may be further crosslinked to form a scaffold. | 09-18-2014 |
20140273154 | DUAL-FUNCTIONAL HYBRID GLUCANASES - Described herein is a fusion polypeptide that contains (a) a first segment containing a | 09-18-2014 |
20140273155 | COMPOSITION AND METHOD FOR PRODUCING SAME - To provide a novel and stable protein composition, and a method for stabilizing the protein composition. A composition that contains protein and water containing ultra-fine air bubbles having a mode particle size of 500 nm or less, and a method for stabilizing a protein composition that involves mixing protein and water containing ultra-fine air bubbles having a mode particle size of 500 nm or less. | 09-18-2014 |
20140287476 | VIBRIO CHOLERAE 0139 CONJUGATE VACCINES - The disclosure pertains to conjugates of the capsular polysaccharide of | 09-25-2014 |
20140295521 | METHOD FOR REDUCING THE IMMUNE RESPONSE TO A BIOLOGICALLY ACTIVE PROTEIN - A new use of a molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal is provided, for preparation of a medicament which elicits no or a reduced immune response upon administration to the mammal, as compared to the immune response elicited upon administration to the mammal of the biologically active protein per se. Also provided is a method of reducing or eliminating the immune response elicited upon administration of a biologically active protein to a human or non-human mammal, which comprises coupling the polypeptide to at least one moiety capable of binding to a serum albumin of the mammal. | 10-02-2014 |
20140302582 | Engineered E2 For Increasing The Content Of Free LYS11-Linked Ubiquitin - The invention provides a chimeric E2 enzyme comprising a Ubc domain fused to a heterologous ubiquitin binding domain (UBD). The chimeric enzymes of the invention may be useful in producing elevated levels of free polyubiquitin. | 10-09-2014 |
20140308730 | CONJUGATES OF BIOMOLECULES TO NANOPARTICLES - Disclosed herein are conjugates comprising a biomolecule linked to a label that have biological activity and are useful in a wide variety of biological applications. For example, provided herein are polymerase-nanoparticle conjugates including a polymerase linked to a nanoparticle, wherein the conjugate has polymerase activity. Such conjugates can exhibit reduced aggregation and improved stochiometries wherein the average biomolecule:nanoparticle ratio approaches or equals 1:1. Also disclosed herein are improved methods for preparing such conjugates, and methods and systems for using such conjugates in biological applications such as nucleotide incorporation, primer extension and single molecule sequencing. | 10-16-2014 |
20140322788 | method for increasing protein thermal stability - The invention provides a simple and effective method for increasing thermal stability of a wide range of proteins, comprising fusing a self-assembling amphipathic peptide to the C- or N-terminal of target proteins. The fusion protein can have a half life up to 26 times longer than that of the wild type protein. | 10-30-2014 |
20140322789 | LINKER-BRIDGED GENE OR DOMAIN FUSION REVERSE TRANSCRIPTASE ENZYME - The present invention relates to combinations of a linker bridged gene or domain fusion reverse transcriptase enzyme, and more particularly, combinations of a linker bridged gene or domain fusion reverse transcriptase enzyme and their fusion construction utilizing for more efficient and quality DNA synthesis in reverse transcription. The composition of the invention includes a polymerase domain; a linker, consisting of 3-40 amino acids; and an RNase H domain, wherein the RNase H domain is either unmodified or modified with point mutations. The composition may further include another mutated RNase H, a mutated RNase A, and an additional linker which consists of 3-40 amino acids. | 10-30-2014 |
20140322790 | METHODS, PEPTIDES AND BIOSENSORS USEFUL FOR DETECTING A BROAD SPECTRUM OF BACTERIA - Described herein are methods of detecting a wound infection and for detecting the presence or absence of bacteria, for example, wound bacteria in a sample, by contacting a sample with a peptide substrate derived from the modification of the reactive site loop (RSL) domain of the α1-proteinase inhibitor. In the current invention, we have demonstrated that these peptide substrates without the alpha 1 protein can be efficiently used as peptide substrates. The modification or the absence of modification of this peptide substrate by the enzyme produced and/or secreted by the bacteria, can serve as an indicator for the presence or absence of the bacteria in the sample. The present invention also features a biosensor for detecting the presence or absence of bacteria in a sample. | 10-30-2014 |
20140322791 | PROCESS TO PREPARE A STABLE THROMBIN COMPOSITION - The stable thrombin composition comprises purified thrombin, human albumin and a neutral salt, the resulting product being stable when stored as a lyophilisate or frozen and is adjusted to a nominal strength of 500 IU of thrombin or more per ml of solution, the human albumin being in a concentration of over 0.05% (w/v) and preferably between 0.1% (w/v) and 1% (w/v). | 10-30-2014 |
20140329290 | NOVEL BRANCHED POLYETHYLENE GLYCOL AND USE THEREOF - The present invention allows formation of covalent bonds in a bioactive compound having at least one amino group so as to efficiently provide the compound modified with PEG. The present invention thus provides a functionalized polyethylene glycol having a structure that allows reaction of two aldehyde groups with one amino group to form two covalent bonds. | 11-06-2014 |
20140349369 | HISTIDYL-TRNA SYNTHETASE-FC CONJUGATES - The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides. | 11-27-2014 |
20140363873 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 12-11-2014 |
20140377836 | CRYSTAL - The present invention relates to a crystal. In particular the present invention relates to a crystal of the N-domain of ACE protein. The present invention also relates to methods, processes, domain specific modulators, pharmaceutical compositions and uses of the N-domain crystal and the structure co-ordinates thereof. | 12-25-2014 |
20140377837 | OLIGOSACCHARIDE MODIFICATION AND LABELING OF PROTEINS - The present invention generally relates to methods of functionalizing proteins, particularly antibodies, at oligosaccharide linkages, methods of humanizing antibodies by modifying glycosylation, as well as to novel antibodies linked to modified oligosaccharides. The invention further relates to kits that may be used to produce the antibodies of the invention. | 12-25-2014 |
20140377838 | STABILIZATION OF BIOMOLECULES USING SUGAR POLYMERS - Compositions and methods for stabilizing biomolecules are disclosed. Specifically, the compositions include novel homopolymers or copolymers containing trehalose side chains conjugated to biomolecules. When such homopolymers or copolymers are placed in close proximity to biomolecules, such as proteins, the homopolymers or copolymers protect and/or stabilize the biomolecule. The compositions and methods may be suitable for use in various industries such as healthcare (pharmaceuticals), molecular biology, biofuels, paper, personal care, detergent, photographic, rubber, brewing, dairy and food processing industries. | 12-25-2014 |
20150024455 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE - The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst. | 01-22-2015 |
20150024456 | Compounds and Methods for Use in Detecting Gabapentin - Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays. | 01-22-2015 |
20150024457 | ANTIBODIES TO TROPONIN I AND METHODS OF USE THEREOF - The subject invention relates to antibodies to troponin I as well as methods of use thereof. In particular, such antibodies may be used to detect Troponin I in a patient and may also be used in the diagnosis of, for example, a myocardial infarction or acute coronary syndrome. | 01-22-2015 |
20150024458 | Dock-and-Lock (DNL) Complexes for Therapeutic and Diagnostic Use - Disclosed herein are methods and compositions dock and lock (DNL) complexes comprising an AD moiety selected from an AKAP protein and a DDD moiety selected from a protein kinase A regulatory subunit. Also disclosed are fusion proteins comprising an AD moiety or DDD moiety attached to an effector moiety. The DDD moieties form dimers that bind to the AD moiety to form the DNL complexes. The effector moieties may be selected from a wide range of known effector moieties that produce one or more physiological effects, including but not limited to cell death. The DNL complexes may further comprise one or more diagnostic and/or therapeutic agents. The DNL complexes are of use for treating and/or diagnosing a variety of diseases or conditions. | 01-22-2015 |
20150024459 | Multivalent Antibody Complexes Targeting IGF-1R Show Potent Toxicity Against Solid Tumors - The present invention concerns methods and compositions comprising an anti-IGF-1R antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer. The anti-IGF-1R antibody or fragment may be part of a complex, such as a DOCK-AND-LOCK™ (DNL™) complex. Preferably, the DNL™ complex also comprises a second antibody, a second antibody fragment, an affibody or a cytokine. More preferably, the cytokine is interferon-α2b. Most preferably, the second antibody, second fragment or affibody binds to IGF-1R, TROP2 or CEACAM6. The anti-IGF-1R antibody or complex may be administered alone or in combination with a therapeutic agent, such as an mTOR inhibitor. | 01-22-2015 |
20150024460 | NPP1 FUSION PROTEINS - The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide. | 01-22-2015 |
20150031106 | HCV PROTEASE INHIBITORS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 01-29-2015 |
20150031107 | PCR REACTION MIXTURES WITH DECREASED NON-SPECIFIC ACTIVITY - The present invention provides methods for improving the specificity of nucleic acid amplification comprising incubating a nucleic acid molecule with a polymerase-Sso7 DNA binding domain conjugate and arginine, spermidine, or spermine. The present invention also provides reaction mixtures and kits for improving the specificity of nucleic acid amplification. | 01-29-2015 |
20150050713 | Technology for the Preparation of Microparticles - Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions. | 02-19-2015 |
20150050714 | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates And Their Preparation - The present invention relates to polymeric reagents and conjugates thereof, methods for synthesizing the polymeric reagents and conjugates, pharmaceutical compositions comprising the conjugates and methods of using the polymer conjugates including therapeutic methods where conjugates are administered to patients. | 02-19-2015 |
20150050715 | Stably Tethered Structures of Defined Compositions with Multiple Functions or Binding Specificities - The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization and docking domain attached to a first precursor, and a second monomer comprising an anchoring domain attached to a second precursor. The first and second precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. The disclosed methods and compositions provide a simple, easy to purify way to obtain any binary compound attached to any monomeric compound, or any trinary compound. | 02-19-2015 |
20150056680 | Methods for Generating Stably Linked Complexes Composed of Homodimers, Homotetramers or Dimers of Dimers and Uses - The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. Other embodiments concern tetramers comprising a first and second homodimer, which may be identical or different. The disclosed methods and compositions provide a facile and general way to obtain homodimers, homotetramers and heterotetramers of virtually any functionality and/or binding specificity. | 02-26-2015 |
20150072396 | Compounds and Methods for Conjugation of Biomolecules - Low-copper click chemistry, 1.3-dipolar cycloadditions, and Staudinger ligations for modifying biomolecules is provided. Compositions, methods, and kits relating to low-copper click chemistry, 1.3-dipolar cycloadditions, and Staudinger ligations are also provided. | 03-12-2015 |
20150079657 | TARGETED HISTONE ACETYLATION - The present disclosure provides compositions and methods for acetylating histones at targeted chromosomal locations in a cell. In particular, the disclosure provides a fusion protein comprising a DNA binding domain and at least one histone acetyltransferase (HAT) domain, such that the DNA binding domain targets the fusion protein to a targeted chromosomal location and the HAT domain acetylates histones at the targeted location. | 03-19-2015 |
20150079658 | Activated Polyoxazolines and Conjugates and Compositions Comprising the Same - The present disclosure provides POZ derivatives having a range of active functional groups allowing conjugation of POZ derivatives to a variety of target molecules under a wide range of reaction conditions to produce a hydrolytically stable target molecule-POZ conjugate. Furthermore, the present disclosure provides novel methods of synthesis for the disclosed POZ derivatives and hydrolytically stable target molecule-POZ conjugates created using the disclosed terminally activated monofunctional POZ derivatives. In one embodiment, the POZ derivative is a terminally activated monofunctional POZ derivative. | 03-19-2015 |
20150087044 | POLYHEDRAL CAGE-CONTAINING MESOPOROUS METAL-ORGANIC FRAMEWORKS AS PLATFORM FOR BIOCATALYSIS, METHODS OF MAKING THESE FRAMEWORKS, AND METHODS OF USING THESE FRAMEWORKS - Embodiments of the present disclosure provide compositions including polyhedral mesoporous metal-organic framework including a biomolecule (e.g., enzyme), methods of making these compositions, methods of use, and the like. | 03-26-2015 |
20150087045 | CRYSTAL STRUCTURE OF HCV POLYMERASE COMPLEXES AND METHODS OF USE - The present disclosure includes a crystalline form and a crystal structure of HCV RNA polymerase and HCV RNA polymerase in a complex with an RNA template primer molecule. In other aspects, the disclosure provides methods of using the crystal structures and structural coordinates to identify homologous proteins and to design or identify agents that can modulate the function of the HCV RNA polymerase and HCV RNA polymerase in a complex with an RNA template primer molecule. | 03-26-2015 |
20150087046 | SPIDER SILK FUSION PROTEIN STRUCTURES WITHOUT REPETITIVE FRAGMENT FOR BINDING TO AN ORGANIC TARGET - A recombinant fusion protein comprising the moieties Band CT is provided. B is a non-spidroin moiety which provides the capacity of selective interaction with an organic target. CT is a moiety of from 70 to 120 amino acid residues and is derived from the C-terminal fragment of a spider silk protein. The fusion protein is not comprising any moiety derived from the repetitive fragment of a spider silk protein. | 03-26-2015 |
20150093800 | METHOD FOR CHROMATOGRAPHY REUSE - The present invention provides methods for cleaning or regenerating a chromatography materiel for reuse. The methods of the invention can be used for cleaning or regenerating chromatography columns for reuse in the large-scale manufacture of multiple polypeptide products. | 04-02-2015 |
20150093801 | Solubilized Phospholipids for Stabilizing Nucleic Acid Polymerases - Compositions and methods are provided that relate to solubilized phospholipids and their use in stabilizing nucleic acid polymerases. For example, a phospholipid with a tail containing at least 8 carbons can be solubilized in the presence of an amphipathic molecule. | 04-02-2015 |
20150104847 | METHOD FOR STABILIZING CHOLESTEROL OXIDASE - The present invention provides a method for stabilizing a cholesterol oxidase, a method for preserving a cholesterol oxidase, and a stabilized composition of cholesterol oxidase. A method for stabilizing a cholesterol oxidase and a method for preserving a cholesterol oxidase which comprises allowing the cholesterol oxidase to coexist with an α-keto acid in an aqueous medium, and, a stabilized composition of cholesterol oxidase which comprises the cholesterol oxidase being allowed to coexist with an α-keto acid in an aqueous medium. The method for stabilizing a cholesterol oxidase, the method for preserving a cholesterol oxidase, and a stabilized composition of cholesterol oxidase according to the present invention are useful for clinical diagnosis such as metabolic syndrome. | 04-16-2015 |
20150111279 | Class I Anti-CEA Antibodies and Uses Thereof - The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer. | 04-23-2015 |
20150118730 | ENZYME-BASED PROTEIN SEPARATION AND ENRICHMENT FROM SOY MEAL, WHEAT MEAL, AND OTHER PROTEIN-RICH MATERIALS DERIVED FROM PLANT SEEDS, FRUITS AND OTHER BIOMASS - The present invention is directed to enzyme based methods for separating protein from protein-rich materials derived from plant seeds, fruit, or other biomass and products made therefrom. The protein content in the resulting products is improved by separating and removing the carbohydrates from around the proteins in, for example, soybean meal. This removal is facilitated by the enzymatic hydrolysis of poly- and oligomeric carbohydrates into monosaccharides and other water soluble sugars. The present invention provides for the production of three streams of useful materials. The first is an enriched protein material comparable to the known SPCs but without significant quantities of undigestible oligosaccharides and polysaccharides. The second is an SPI made from the soluble protein in the hydrolysate which is valuable for high-quality feed, food and industrial uses. The third is the soluble saccharides and hydrolyzed carbohydrates (releasing sugars) that can be converted by fermentation to various valuable bioproducts. | 04-30-2015 |
20150118731 | ANTIMICROBIAL AGENTS - The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions comprising the same. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. | 04-30-2015 |
20150147798 | METHOD FOR STABILIZING ASCORBIC ACID OXIDASE - Provided are: a method for stabilizing an ascorbic acid oxidase; a method for preserving an ascorbic acid oxidase; and a stabilized composition of an ascorbic acid oxidase. A method for stabilizing an ascorbic acid oxidase and a method for preserving an ascorbic acid oxidase, each of the methods comprising allowing an ascorbic acid oxidase to coexist with nitrous acid or a salt thereof, or a nitrous acid ester in an aqueous medium; and a stabilized composition of an ascorbic acid oxidase, which comprises an ascorbic acid oxidase being allowed to coexist with nitrous acid or a salt thereof, or a nitrous acid ester in an aqueous medium. The method for stabilizing an ascorbic acid oxidase, the method for preserving an ascorbic acid oxidase, and the stabilized composition of an ascorbic acid oxidase according to the present invention are useful for clinical diagnosis and the like. | 05-28-2015 |
20150291961 | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX - Isolation or in vitro assembly of the Cas9-crRNA complex of the | 10-15-2015 |
20150307633 | Polysialic Acid Derivatives - A polysialic acid compound is reacted with a hetero-bifunctional reagent to introduce a pendant functional group for site-specific conjugation to sulfhydryl groups, for instance side chains of cysteine units in drugs, drug delivery systems, proteins or peptides. The functional group is, for instance, an N-maleimide group. | 10-29-2015 |
20150307859 | Cell Penetrating Peptide, Conjugate Comprising Same, and Composition Comprising Conjugate - The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 156, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 156, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed. | 10-29-2015 |
20150315280 | PREVENTIVE OR REMEDY FOR INFLAMMATORY DISEASE - The present inventors obtained, from a phage library of human antibodies, an anti-mouse NR 10 neutralizing antibody-expressing BM095 clone that shows a strong proliferation-suppressing activity in an IL-31-dependent Ba/F3 cell proliferation assay system. When this anti-mouse NR 10 neutralizing antibody was administered to NC/Nga mice, a model of atopic dermatitis which is a mouse model of chronic dermatitis that arises as a result of repeated applications of picryl chloride, a mouse model of rheumatoid arthritis, and a mouse model of osteoarthritis, a significant effect of symptom suppression was observed. This revealed that the anti-NR 10 neutralizing antibody is indeed effective as a therapeutic agent for inflammatory diseases. In addition, the present inventors successfully obtained an anti-human NR 10 neutralizing antibody, providing extremely useful therapeutic agents with practical clinical applications. | 11-05-2015 |
20150320872 | Anti-Mucin Antibodies for Early Detection and Treatment of Pancreatic Cancer - Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to pancreatic cancer mucins such as MUC1 or MUC5ac and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay. Alternatively, immunoassay with PAM4 and anti-CA19.9 antibodies may be utilized to improve sensitivity for pancreatic cancer. | 11-12-2015 |
20150329849 | FORMULATIONS AND METHODS FOR STABILIZING PCR REAGENTS - Described herein are stabilized polymerase compositions comprising a polymerase and an polymerase stabilizing agent, such as a non-detergent zwitterionic stabilizer or a cationic ester disclosed, for use in nucleic acid amplification or nucleic acid sequencing. Compositions are provided for the stabilization of one or more polymerases in a single stabilized liquid formulation. Also disclosed are methods for making and using stabilized polymerase compositions and kits for nucleic acid amplification and sequencing comprising the stabilized polymerase compositions provided. | 11-19-2015 |
20150337282 | STABILIZATION OF THERMOLYSIN IN AQUEOUS SOLUTION - The present invention deals with the proteolytic enzyme thermolysin which tends to be unstable in aqueous solution. The invention provides methods and compositions to enhance the stability of dissolved thermolysin in aqueous solution. Thermolysin, crude thermolysin or a lyophilisate containing thermolysin and one or more salts, is contacted with an aqueous buffer with a low salt concentration and a first solution is formed. Subsequently, a further salt in solid form is added and dissociated, thereby forming a second solution comprising thermolysin in a stabilized form. | 11-26-2015 |
20150344549 | SPLIT INTEINS, CONJUGATES AND USES THEREOF - Disclosed herein are split inteins, fused proteins of split inteins, and methods of using split inteins to efficiently purify and modify proteins of interest. Thus, provided herein are fusion proteins of a polypeptide and a split intein N-fragment, or variant thereof, as described below in greater detail. Also provided are complexes of the fusion protein and a split intein C-fragment or variant thereof as described in detail below. The complex of the fusion protein and C-fragment or variant thereof can be via a covalent interaction between the fusion protein and C-fragment or variant or via a noncovalent interaction (e.g., ionic, H-bonding, and/or van der Waals interaction). Further provided herein are split intein C-fragments or variants thereof. | 12-03-2015 |
20150344932 | METHOD AND COMPOSITIONS FOR THE DETECTION OF PROTEIN GLYCOSYLATION - The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with posttranslational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engine˜red mutant of β-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes. | 12-03-2015 |
20150374846 | Methods and Compositions for Generating Bioactive Assemblies of Increased Complexity and Uses - The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition. | 12-31-2015 |
20160002613 | Cell Penetrating Peptide, Conjugate Comprising Same, and Composition Comprising Conjugate - The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 6, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 6, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed. | 01-07-2016 |
20160024122 | BIOREVERSIBLE BORONATES FOR DELIVERY OF MOLECULES INTO CELLS - Methods for enhancing cellular uptake of cargo molecules by boronating the cargo molecule, particularly with one or more phenylboronic acid groups. Boronation reagents for reversible boronation of cargo molecules, particularly, cargo molecules having one or more amino groups are provided. | 01-28-2016 |
20160040141 | STABILIZED TRANSGLUTAMINASE AND PROCESS FOR PRODUCTION THEREOF - Disclosed is a transglutaminase having excellent stability. Also disclosed is a process for producing the transglutaminase. Specifically disclosed is a stabilized transglutaminase, which has such a structure in which a pro-sequence peptide of transglutaminase is bound to a mature transglutaminase. Also specifically disclosed is a process for producing stabilized transglutaminase, which includes the steps of culturing a microorganism capable of producing transglutaminase under the conditions where transglutaminase can be produced; and separating and collecting matured transglutaminase having a pro-sequence peptide bound thereto from a culture medium. | 02-11-2016 |
20160053336 | POLYPEPTIDES HAVING DEXTRANASE ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME - The present invention relates to isolated polypeptides having dextranaseactivity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides. | 02-25-2016 |
20160060614 | Thrombin Solution And Methods Of Use Thereof - Provided are methods for lyophilization of an aqueous thrombin solution, thrombin solutions for use in such lyophilization methods, and solid thrombin compositions produced by such methods. | 03-03-2016 |
20160060654 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION - The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms. | 03-03-2016 |
20160068834 | STABLIZED EZH2 PEPTIDES - Provided herein are polypeptides containing stabilized therapeutic peptides related to enhancer of zeste homolog 2 (EZH2), histone lysine N-methyltransferase. Also provided are compositions containing these polypeptides and methods of using such peptides in the treatment of cancer that include administering to a subject one of the polypeptides. | 03-10-2016 |
20160068864 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION - The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms. | 03-10-2016 |
20160075627 | ORGANIC COMPOUNDS - An aryl-substituted alkanal compound having a molecular weight of less than 300 g/mol and which bears a substituent on the aryl ring ortho to a substituent bearing the aldehyde functionality. Said compounds are useful as perfume ingredients in personal care and household care products. | 03-17-2016 |
20160076007 | COENZYME-LINKED GLUCOSE DEHYDROGENASE AND POLYNUCLEOTIDE ENCODING THE SAME - The present invention provides members that produce on a large scale a coenzyme-linked glucose dehydrogenase which has excellent substrate-recognizing ability toward glucose while providing low action on maltose. The present invention relates to a polynucleotide encoding a soluble coenzyme-linked glucose dehydrogenase that catalyzes the oxidation of glucose in the presence of an electron acceptor and has an activity toward maltose of 5% or lower; a polypeptide encoded by the nucleotide sequence of the polynucleotide; a recombinant vector carrying the polynucleotide; a transformed cell produced using the recombinant vector; a method for producing a polypeptide comprising culturing the transformed cell and collecting from the cultivated products a polypeptide that links to FAD to exert the glucose dehydration activity; a method for determination of glucose using the polypeptide; a reagent composition for determination of glucose; and a biosensor. | 03-17-2016 |
20160083450 | HUMAN PROTEIN SCAFFOLD WITH CONTROLLED SERUM PHARMACOKINETICS - This invention provides constructs comprising a protein scaffold, wherein the scaffold comprises Domain III, Domain IIIa, or Domain IIIb of human serum albumin or a polypeptide having substantial sequence identity to the Domain III, the Domain IIIa, or the Domain IIIb; and a targeting moiety in covalent linkage to the protein scaffold; and a therapeutic moiety and/or an imaging moiety in covalent linkage to the protein scaffold. The scaffold can be modified to tune the serum pharmacokinetics of the construct. In addition to methods of making the constructs, therapeutic, imaging and diagnostic uses of the constructs are also provided. | 03-24-2016 |
20160083706 | BORONATE-MEDIATED DELIVERY OF MOLECULES INTO CELLS - Cargo molecules carrying one or more phenylboronate moieties useful for cellular uptake of the cargo molecules. Phenylboronate can be ligated, crosslinked or otherwise bonded to the cargo molecules. Cargo molecules include peptides and proteins. The phenylboronate groups are optionally conjugated to the cargo molecule via linking moieties that can be selectively cleaved, such cleavable linkers can allow the phenylboronate groups to be removed from the cargo molecule after the boronated cargo molecule is introduced into the cell. The invention includes certain phenylboronates which are boronation reagents, certain boronated oligopeptides and certain boronated peptides and proteins. The invention also includes kits for enhancing cellular uptake of cargo molecules by boronation with one or more phenylboronates or boronated oligopeptides. | 03-24-2016 |
20160090413 | ANTI-MUCIN ANTIBODIES FOR EARLY DETECTION AND TREATMENT OF PANCREATIC CANCER - Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to an epitope located within the second to fourth cysteine-rich domains of MUC5ac (amino acid residues 1575-2052) and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay. | 03-31-2016 |
20160090583 | ENGINEERED HEME-BINDING COMPOSITIONS AND USES THEREOF - Described herein are heme-binding compositions and methods relating to their use, e.g. methods of treatment of for example, sepsis and rhabdomyolysis. | 03-31-2016 |
20160097081 | INTERNALIZATION OF PROTEINS INTO HOLLOWED GOLD NANOSTRUCTURES - Provided is a gold nanocage with pores, charged ligand molecules covalently bound to internal surfaces of the gold nanocage, and payload molecules electrostatically adsorbed onto said charged ligand molecules, wherein a pore diameter is between 1.2 and 20 times a gyration radius of the payload molecule. Also provided is a method for making a nanoparticle, including using polyvinylpyrrolidone as a capping agent in a galvanic replacement reaction to convert a silver nanocube into a gold nanocage having pores, replacing the polyvinylpyrrolidone on internal surfaces with charged ligand molecules, and electrostatically adsorbing payload molecules onto the charged ligand molecules, with a pore diameter less than twenty times a gyration radius of the payload molecule. Also provided is a method of delivering a pharmacological agent to a mammalian cell, including contacting the cell with a gold nanocage having pores, ligand molecules bound to internal surfaces, and pharmacological agent adsorbed onto ligand molecules. | 04-07-2016 |
20160101190 | POLYMER-BASED PROTEIN ENGINEERING METHODS TO RATIONALLY TUNE ENZYME ACTIVITY, pH-DEPENDENCE AND STABILITY - Using a novel water-soluble, active ester amide-containing functionalized controlled radical polymerization initiator, stimuli responsive polymers have been grown from the surface of a protein, exemplified by chymotrypsin or any protein having surface amino acids that will covalently bind to the active ester amide-containing functionalized initiator. It is shown that changes in temperature or pH can change the conformation of the polymer surrounding the enzyme, which in turn enabled the rational tailoring of enzyme activity and stability. This method has afforded an increase in the activity and stability of the enzyme by an order of magnitude at pH's where the enzyme is usually inactive or unstable. Multimodal temperature responsive protein-block copolymer conjugates are described. | 04-14-2016 |
20160108095 | POLYPEPTIDES - The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for treatment or diagnosis of disease in mammals including humans. | 04-21-2016 |
20160108390 | COMPOSITION FOR STABILIZING EC-SOD AND METHOD OF STABILIZING EC-SOD USING THE SAME - The present invention relates to a composition for stabilizing extracellular superoxide dismutase (EC-SOD) protein and a method for stabilizing EC-SOD protein using the composition. More particularly, the present invention relates to a composition for stabilizing EC-SOD protein comprising bovine serum albumin (BSA), human serum albumin (HSA), polyethylene glycol (PEG) or fetal bovine serum (FBS) as an effective ingredient; a method for stabilizing EC-SOD protein using the inventive composition; and a method for preparing a stabilized EC-SOD protein using the inventive composition. | 04-21-2016 |
20160114053 | METHODS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS WITH ENHANCED PHARMACOLOGICAL PROPERTIES - Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP. | 04-28-2016 |
20160120994 | BLOOD COAGULATION PROTEIN CONJUGATES - The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a blood coagulation protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer. In one embodiment of the invention the conjugation is carried out in the presence of the nucleophilic catalyst aniline. In addition the generated oxime linkage can be stabilized by reduction with NaCNBH | 05-05-2016 |
20160120997 | Modified Glycoproteins Having Circulating Half-Lives - Method of conjugating glycoproteins by means of chemical modification is provided as well as new modified glycoproteins. | 05-05-2016 |
20160129126 | CHEMICAL CROSSLINKERS - Disclosed herein are methods of chemical conjugation comprising contacting a lysosomal enzyme with a first crosslinking agent to introduce aldehyde groups; contacting a lysosomal targeting peptide with a second crosslinking agent to introduce a hydrazide group at the N-terminal residue; contacting the lysosomal enzyme with aldehyde groups of step a. with the lysosomal targeting peptide with a hydrazide group at the N-terminal residue of step b; and forming a lysosomal enzyme-lysosomal targeting peptide conjugate. | 05-12-2016 |
20160130344 | ANTI-GCC ANTIBODY MOLECULES AND METHODS FOR USE OF SAME - Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein. | 05-12-2016 |
20160130568 | THERMOPHILIC AND THERMOACIDOPHILIC GLYCOSYLATION GENES AND ENZYMES FROM ALICYCLOBACILLUS ACIDOCALDARIUS AND RELATED ORGANISMS, METHODS - Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from | 05-12-2016 |
20160138002 | ANTIBODY-UREASE CONJUGATES - This disclosure provides antibody-urease conjugates having therapeutic and diagnostic utility. More specifically, the disclosure relates to diagnostic and/or therapeutic conjugates that are prepared by conjugating one or more whole antibodies to ease. | 05-19-2016 |
20160144046 | POLYMERIC ALPHA-HYDROXY ALDEHYDE AND KETONE REAGENTS AND CONJUGATION METHOD - Provided herein are polymeric α-hydroxy aldehyde or α-hydroxy ketone reagents which can be conjugated to amine-containing compounds to form stable conjugates in a single-step reaction. In selected embodiments, the polymeric reagent itself incorporates an internal proton-abstracting (basic) functional group, to promote more efficient reaction. The substituent is appropriately situated, via a linker if necessary, to position the group for proton abstraction, preferably providing a 4- or 5-bond spacing between the abstracting atom and the hydrogen atom on the α-carbon. Also provided are methods of using the reagents and stable, solubilized conjugates of the reagents with biologically active compounds. In preferred embodiments, the polymeric component of the reagent or conjugate is a polyethylene glycol. | 05-26-2016 |
20160144051 | LOGIC ELEMENT COMPLEX BASED ON BIOMOLECULES (VARIANTS) - The invention relates to the field of logic elements, specifically to logic elements based on biomolecules. The essence of the invention consists in a logic element complex which converts input signals into an output action according to a given logic function. Depending on the output action, the proposed logic element complex can be used both for computational purposes and for various applications in biomedicine, e.g., for diagnostics or therapy of diseases, targeted delivery of a substance to target cells, etc. The technical result when using the invention consists in a logic element complex, for which a plurality of input signals and output actions can be virtually unlimited, said signals and output actions can be different in nature, and, in addition, implementation of a wide range of logic functions for the same input signals is made possible. | 05-26-2016 |
20160160206 | Aldehyde-Tagged Protein-Based Drug Carriers and Methods of Use - The disclosure provides aldehyde-tagged protein carriers that can be covalently and site-specifically bound to drug to provide a drug-containing scaffold. The invention also encompasses methods of production of such drug-containing scaffolds and intermediates, as well as methods of use. | 06-09-2016 |
20160168558 | Compositions, Methods and Kits for Real-Time Nucleic Acid Analysis in Live Cells | 06-16-2016 |
20160177289 | REACTION MIXTURES | 06-23-2016 |
20160177397 | APTAMER FOR DETECTION OF ALPHA-METHYLACYL-COA RACEMASE AND DIAGNOSTIC KIT THEREOF | 06-23-2016 |
20160187324 | Antibody Conjugates - Antibody/signal-generating moiety conjugates are disclosed that include an antibody covalently linked to a signal-generating moiety through a heterobifunctional polyalkyleneglycol linker. The disclosed conjugates show exceptional signal-generation in immunohistochemical and in situ hybridization assays on tissue sections and cytology samples. In one embodiment, enzyme-metallographic detection of nucleic acid sequences with hapten-labeled probes can be accomplished using the disclosed conjugates as a primary antibody without amplification. | 06-30-2016 |
20160195540 | Molecular Conjugate | 07-07-2016 |
20160251467 | SITE SPECIFICALLY INCORPORATED INITIATOR FOR GROWTH OF POLYMERS FROM PROTEINS | 09-01-2016 |
20160251637 | COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODS | 09-01-2016 |
20190142958 | THERAPEUTIC PROTEINS WITH INCREASED HALF-LIFE AND METHODS OF PREPARING SAME | 05-16-2019 |